

SCHERING PLOUGH CORP  
Form 10-Q  
August 01, 2008

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 10-Q**

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities  
Exchange Act of 1934**  
**For the quarterly period ended June 30, 2008**

**Commission file number 1-6571**

**SCHERING-PLOUGH CORPORATION**  
*(Exact name of registrant as specified in its charter)*

**New Jersey**  
*State or other jurisdiction of  
incorporation or organization*  
**2000 Galloping Hill Road, Kenilworth, NJ**  
*(Address of principal executive offices)*

**22-1918501**  
*(I.R.S. Employer  
identification No.)*  
**07033**  
*Zip Code*

**Registrant's telephone number, including area code:**  
**(908) 298-4000**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

Common Shares Outstanding as of June 30, 2008: 1,625,591,985



**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES****STATEMENTS OF CONDENSED CONSOLIDATED OPERATIONS****(Unaudited)****(Amounts in millions, except per share figures)**

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
Net sales	\$ 4,921	\$ 3,178	\$ 9,577	\$ 6,153
Cost of sales	1,908	977	4,044	1,913
Selling, general and administrative	1,870	1,358	3,547	2,572
Research and development	906	696	1,786	1,403
Other expense/(income), net	134	(16)	229	(62)
Special and acquisition-related charges	94	11	117	12
Equity income	(493)	(490)	(1,010)	(978)
Income before income taxes	502	642	864	1,293
Income tax expense	66	103	138	190
Net income	436	539	726	1,103
Preferred stock dividends	38	22	75	43
Net income available to common shareholders	\$ 398	\$ 517	\$ 651	\$ 1,060
Diluted earnings per common share	\$ 0.24	\$ 0.34	\$ 0.40	\$ 0.70
Basic earnings per common share	\$ 0.25	\$ 0.35	\$ 0.40	\$ 0.71
Dividends per common share	\$ 0.065	\$ 0.065	\$ 0.13	\$ 0.13

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**  
**STATEMENTS OF CONDENSED CONSOLIDATED CASH FLOWS**

(Unaudited)  
(Amounts in millions)

	<b>Six Months Ended</b>	
	<b>June 30,</b>	
	<b>2008</b>	<b>2007</b>
<b>Operating Activities:</b>		
Net income	\$ 726	\$ 1,103
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,419	243
Accrued share-based compensation	118	88
Special and acquisition-related charges and payments	58	(438)
Purchase of derivative currency option		(130)
Change in fair value of foreign currency option		31
Changes in assets and liabilities:		
Accounts receivable	(407)	(293)
Inventories	(112)	(16)
Prepaid expenses and other assets	(14)	(99)
Accounts payable	(21)	106
Other liabilities	(383)	33
Net cash provided by operating activities	1,384	628
<b>Investing Activities:</b>		
Capital expenditures	(370)	(275)
Dispositions of property and equipment	31	1
Purchases of short-term investments		(1,182)
Maturities of short-term investments	10	3,065
Other, net		(11)
Net cash (used for)/provided by investing activities	(329)	1,598
<b>Financing Activities:</b>		
Payments of long-term debt	(325)	
Cash dividends paid to common shareholders	(211)	(179)
Cash dividends paid to preferred shareholders	(75)	(43)
Net change in short-term borrowings	(40)	(10)
Stock option exercises	4	177
Other, net	(2)	(2)
Net cash used for financing activities	(649)	(57)
Effect of exchange rates on cash and cash equivalents	20	18

<b>Net increase in cash and cash equivalents</b>	426	2,187
<b>Cash and cash equivalents, beginning of period</b>	2,279	2,666
<b>Cash and cash equivalents, end of period</b>	\$ 2,705	\$ 4,853

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(Unaudited)****(Amounts in millions, except per share figures)**

	<b>June 30, 2008</b>	<b>December 31, 2007</b>
<b>ASSETS</b>		
<b>Current Assets:</b>		
Cash and cash equivalents	\$ 2,705	\$ 2,279
Short-term investments	22	32
Accounts receivable, net	3,381	2,841
Inventories	3,478	4,073
Deferred income taxes	518	349
Prepaid expenses and other current assets	1,262	1,272
Total current assets	11,366	10,846
Property, plant and equipment	10,918	10,354
Less accumulated depreciation	3,728	3,338
Property, net	7,190	7,016
Goodwill	3,064	2,937
Other intangible assets, net	7,098	7,004
Other assets	1,403	1,353
<b>Total assets</b>	<b>\$ 30,121</b>	<b>\$ 29,156</b>

**LIABILITIES AND SHAREHOLDERS EQUITY**

<b>Current Liabilities:</b>		
Accounts payable	\$ 1,787	\$ 1,762
Short-term borrowings and current portion of long-term debt	456	461
Income taxes	464	617
Accrued compensation	799	995
Other accrued liabilities	2,252	2,208
Total current liabilities	5,758	6,043
<b>Long-term Liabilities:</b>		
Long-term debt, net of current portion	9,015	9,019
Deferred income taxes	1,793	1,701
Other long-term liabilities	2,201	2,008
Total long-term liabilities	13,009	12,728
Commitments and contingent liabilities (Note 17)		
<b>Shareholders Equity:</b>		

Edgar Filing: SCHERING PLOUGH CORP - Form 10-Q

2007 Mandatory convertible preferred shares \$1 par value; \$250 per share face value; issued: 10 at June 30, 2008 and December 31, 2007	2,500	2,500
Common shares authorized shares: 2,400, \$.50 par value; issued: 2,117 at June 30, 2008 and 2,111 at December 31, 2007	1,059	1,055
Paid-in capital	4,933	4,815
Retained earnings	8,293	7,856
Accumulated other comprehensive loss	(89)	(534)
<b>Total</b>	<b>16,696</b>	<b>15,692</b>
Less treasury shares: 492 at June 30, 2008 and 490 at December 31, 2007; at cost	5,342	5,307
<b>Total shareholders equity</b>	<b>11,354</b>	<b>10,385</b>
<b>Total liabilities and shareholders equity</b>	<b>\$ 30,121</b>	<b>\$ 29,156</b>

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1. BASIS OF PRESENTATION**

These unaudited Condensed Consolidated Financial Statements of Schering-Plough Corporation and subsidiaries (Schering-Plough), have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles have been condensed or omitted pursuant to such SEC rules and regulations. These statements should be read in conjunction with the accounting policies and notes to consolidated financial statements included in Schering-Plough's 2007 10-K/A.

In the opinion of Schering-Plough's management, these financial statements reflect all adjustments necessary for a fair presentation of the statements of operations, cash flows and financial position for the interim periods presented.

In November 2007, Schering-Plough acquired Organon BioSciences N.V. (OBS), a company that discovers, develops and manufactures human prescription and animal health products. See Note 2, Acquisition, for additional information.

***Impact of Recently Issued Accounting Standards***

In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements. The standard defines fair value, establishes a framework for measuring fair value in accordance with Generally Accepted Accounting Principles, and expands disclosures about fair value measurements. The standard codifies the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard clarifies the principle that fair value should be based on the assumptions market participants would use when pricing the asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. For calendar-year companies, the standard became effective January 1, 2008 (see Note 15, Fair Value Measurements) except for non-financial items measured on a non-recurring basis for which it is effective beginning January 1, 2009. The implementation of this standard did not have a material impact on Schering-Plough's financial statements. Based on Schering-Plough's current financial position, the impact of the provisions of this standard that will be effective January 1, 2009 is not expected to be material.

In November 2006, the FASB issued Emerging Issues Task Force (EITF) Issue No. 06-10, Accounting for Deferred Compensation and Postretirement Benefits Aspects of Collateral Assignment Split-Dollar Life Insurance Arrangements, which became effective for calendar-year companies on January 1, 2008. The Task Force concluded that an employer should recognize a liability for the postretirement benefit related to a collateral assignment split-dollar life insurance arrangement in accordance with either FASB Statement No. 106 or Accounting Principles Board (APB) Opinion No. 12 based on the substantive agreement with the employee. The Task Force also concluded that an employer should recognize and measure an asset based on the nature and substance of the collateral assignment split-dollar life insurance arrangement. The implementation of this standard did not have a material impact on Schering-Plough's financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities-Including an Amendment of FASB Statement No. 115 (SFAS 159), which permits entities to choose to measure many financial instruments and certain other items at fair value. SFAS 159 also includes an amendment to SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, which applies to all entities with



available-for-sale and trading securities. For calendar-year companies, the standard became effective January 1, 2008. Schering-Plough chose not to elect the fair value option prescribed

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

by SFAS 159. As a result, the implementation of this standard did not have a material impact on Schering-Plough's financial statements.

In June 2007, the FASB issued EITF Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities, which became effective for calendar-year companies on January 1, 2008. The Task Force concluded that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. Such amounts should be recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided. The implementation of this standard did not have a material impact on Schering-Plough's financial statements.

In December 2007, the FASB issued EITF Issue No. 07-1, Accounting for Collaborative Arrangements, which is effective for calendar-year companies beginning January 1, 2009. The Task Force clarified the manner in which costs, revenues and sharing payments made to, or received by, a partner in a collaborative arrangements should be presented in the income statement and set forth certain disclosures that should be required in the partners' financial statements. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In December 2007, the SEC issued Staff Accounting Bulletin (SAB) No. 110, which permits entities, under certain circumstances, to continue to use the simplified method of estimating the expected term of plain vanilla options as discussed in SAB No. 107 and in accordance with FASB SFAS No. 123 (Revised 2004), Share-Based Payment (SFAS 123R). The guidance in this release became effective January 1, 2008. The implementation of this standard did not have a material impact on Schering-Plough's financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations, (SFAS 141R). For calendar-year companies, the standard is applicable to new business combinations occurring on or after January 1, 2009. SFAS 141R requires an acquiring entity to recognize all the assets acquired and liabilities assumed in a transaction at the acquisition-date fair value with limited exceptions. Most significantly, SFAS 141R will require that acquisition costs generally be expensed as incurred, certain acquired contingent liabilities be recorded at fair value, and acquired in-process research and development be recorded at fair value as an indefinite-lived intangible asset at the acquisition date. The standard will also impact certain unresolved matters related to purchase transactions consummated prior to the effective date of the standard. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements An Amendment of ARB No. 51, which is effective for calendar-year companies beginning January 1, 2009. The standard establishes new accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities, an Amendment of FASB Statement No. 133, which is effective for calendar-year companies beginning January 1, 2009. The standard enhances required disclosures regarding derivatives and hedging activities. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In April 2008, the FASB issued FASB Staff Position (FSP) No. FAS 142-3, Determination of the Useful Life of Intangible Assets (FSP 142-3). FSP 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, Goodwill and Other Intangible Assets (SFAS 142). FSP 142-3 is effective for calendar-year companies beginning January 1, 2009. The requirement for determining useful lives must be applied prospectively to intangible assets acquired after the effective date and the disclosure requirements must be

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

applied prospectively to all intangible assets recognized as of, and subsequent to, the effective date. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In May 2008, the FASB issued SFAS No. 162, *The Hierarchy of Generally Accepted Accounting Principles*. This standard identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements that are presented in conformity with generally accepted accounting principles (GAAP) in the United States (the GAAP hierarchy). The standard is effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board amendments to AU Section 411, *The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles*. Schering-Plough is currently assessing the potential impacts of implementing this standard.

In June 2008, the FASB issued FSP EITF No. 03-6-1, *Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities*. The FSP addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and therefore need to be included in the earnings allocation in calculating earnings per share under the two-class method described in SFAS No. 128, *Earnings per Share*. The FSP requires companies to treat unvested share-based payment awards that have non-forfeitable rights to dividend or dividend equivalents as a separate class of securities in calculating earnings per share. The FSP is effective for calendar-year companies beginning January 1, 2009. Schering-Plough is currently assessing the potential impacts of implementing this standard.

**2. ACQUISITION**

Schering-Plough acquired Organon BioSciences N.V. (OBS) for a purchase price of approximately Euro 11 billion in cash, or approximately \$16.1 billion (including legal and professional fees) on November 19, 2007 (the Acquisition Date). This acquisition added further diversification of marketed human prescription products, including two new therapeutic areas (Women's Health and Central Nervous System), significant strength in Animal Health products and new research and development projects. The purchase method of accounting was used to account for the transaction in accordance with SFAS No. 141, *Business Combinations*. The operating results of OBS are included in Schering-Plough's consolidated financial statements for the period subsequent to the Acquisition Date.

A preliminary allocation of the purchase price of OBS was made as of the Acquisition Date. This allocation of the purchase price remains subject to the finalization of Schering-Plough's management analysis of the fair value of the assets acquired (including assets related to pension plans) and liabilities assumed of OBS as of the Acquisition Date. As of June 30, 2008, the allocation of the purchase price to goodwill has decreased by \$32 million as compared to the preliminary allocation as of the Acquisition Date. This adjustment to the preliminary purchase price allocation was primarily related to updated valuations of identifiable intangible assets, property and inventories partially offset by additional acquisition-related liabilities. The final allocation of the purchase price may result in additional adjustments to the recorded amounts of assets and liabilities and may also result in adjustments to depreciation, amortization and acquired in-process research and development. The adjustments arising out of the finalization of the purchase price allocation will not impact cash flows. However, such adjustments could result in material increases or decreases to net income/(loss) available to common shareholders. Further revisions to the purchase price allocation will be made as additional information becomes available. The final allocation is expected to be completed no later than 12 months after the Acquisition Date.

Purchase accounting items of \$1.048 billion related to the amortization of inventory, identifiable intangible assets and property, plant and equipment are included in depreciation and amortization in the Statement of Condensed Consolidated Cash Flows for the six months ended June 30, 2008.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The updated preliminary purchase price allocation of acquired identifiable intangible assets, which resulted in a change in total intangible assets acquired of \$46 million, is as follows:

	<b>Amount (Dollars in millions)</b>	<b>Weighted-Average Amortization Period (years)</b>
Patents:		
Women's Health Contraception	\$ 1,659	11
Women's Health Fertility	1,013	11
Women's Health Other	440	13
Central Nervous System	527	12
Other Human Prescription Pharmaceuticals	382	8
 Total patents	 \$ 4,021	
Trademarks:		
Animal Health	\$ 2,608	20
Human Prescription Pharmaceuticals	210	20
 Total trademarks	 \$ 2,818	
 Total intangible assets acquired	 \$ 6,839	

The weighted-average life of total acquired intangibles is approximately 15 years. The intangible assets have no significant residual value. There were no acquired intangible assets that were determined to have an indefinite life.

**3. SPECIAL AND ACQUISITION-RELATED CHARGES**

Special and acquisition-related charges are as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Special and acquisition-related charges	94	11	117	12

The special and acquisition-related costs for the three and six months ended June 30, 2008 included employee termination costs of \$77 million and \$84 million, respectively. See Note 4, OBS Integration and Productivity Transformation Program, for additional information. During the six months ended June 30, 2008, Schering-Plough made cash payments of \$59 million for special and acquisition-related activities.

The special and acquisition related costs for the three and six months ended June 30, 2007 were \$11 million and \$12 million, respectively, comprised of acquisition related charges (integration planning) for the planned OBS acquisition.

During the six months ended June 30, 2007, Schering-Plough made cash payments of \$435 million, for the settlement of an investigation by the U.S. Attorney's Office for the District of Massachusetts involving certain of Schering-Plough's sales, marketing and clinical trial practices and programs (the Massachusetts Investigation), cash payments of \$9 million of employee termination costs related to the 2006 manufacturing streamlining and \$6 million related to integration planning.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**4. OBS INTEGRATION AND PRODUCTIVITY TRANSFORMATION PROGRAM**

As part of the preliminary purchase price allocation of the OBS acquisition as of the Acquisition Date, Schering-Plough recorded acquisition-related liabilities of \$151 million related to involuntary termination benefits.

In April 2008, Schering-Plough announced a major new program, the Productivity Transformation Program (PTP), which includes the ongoing integration of OBS, and is designed to reduce and avoid costs, and increase productivity. The targeted savings envisioned by this program include those resulting from the previously announced OBS integration synergies.

The following table summarizes the charges, cash payments and liabilities related to PTP, which includes the ongoing integration of OBS, through June 30, 2008:

	<b>Employee Termination Costs(a)</b>	<b>Employee Termination Costs</b>	<b>Acquisition- Related Liabilities(c)</b>	<b>Other Exit Costs</b>
	<b>(Dollars in millions)</b>			
Accrued liability at December 31, 2007	\$ 23(b)	\$ 151		
Charges	84			
Purchase price allocation items			(6)	48
Cash payments	(27)	(64)		(6)
Accrued liability at June 30, 2008	\$ 80	\$ 81		\$ 42

(a) Recorded to special and acquisition-related charges.

(b) Represents employee termination costs recorded under SFAS No. 112, Employers Accounting for Postemployment Benefits, in the fourth quarter of 2007.

(c) Recorded as part of purchase accounting. Included in acquisition-related liabilities at June 30, 2008 are involuntary termination benefits and costs to exit certain activities of OBS.

**5. EQUITY INCOME**

In May 2000, Schering-Plough and Merck & Co., Inc. (Merck) entered into two separate sets of agreements to jointly develop and market certain products in the U.S. including (1) two cholesterol-lowering drugs and (2) an allergy/asthma drug. In December 2001, the cholesterol agreements were expanded to include all countries of the world except Japan. In general, the companies agreed that the collaborative activities under these agreements would



operate in a virtual joint venture to the maximum degree possible by relying on the respective infrastructures of the two companies. These agreements generally provide for equal sharing of development costs and for co-promotion of approved products by each company.

The cholesterol agreements provide for Schering-Plough and Merck to jointly develop and commercialize ezetimibe in the cholesterol management field:

- i. as a once-daily monotherapy (marketed as ZETIA in the U.S. and Asia and EZETROL in Europe);
- ii. in co-administration with various approved statin drugs; and
- iii. as a fixed-combination tablet of ezetimibe and simvastatin (Zocor), Merck's cholesterol-modifying medicine. This combination medication (ezetimibe/simvastatin) is marketed as VYTORIN in the U.S. and as INEGY in many international countries.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

ZETIA/EZETROL (ezetimibe) and VYTORIN/INEGY (the combination of ezetimibe/simvastatin) are approved for use in the U.S. and have been launched in many international markets.

Schering-Plough utilizes the equity method of accounting in recording its share of activity from the Merck/Schering-Plough cholesterol joint venture. As such, Schering-Plough's net sales do not include the sales of the cholesterol joint venture. The cholesterol joint venture agreements provide for the sharing of operating income generated by the cholesterol joint venture based upon percentages that vary by product, sales level and country. In the U.S. market, Schering-Plough receives a greater share of profits on the first \$300 million of annual ZETIA sales. Above \$300 million of annual ZETIA sales, Merck and Schering-Plough generally share profits equally. Schering-Plough's allocation of the cholesterol joint venture income is increased by milestones recognized. Further, either company's share of the cholesterol joint venture's income from operations is subject to a reduction if that company fails to perform a specified minimum number of physician details in a particular country. The companies agree annually to the minimum number of physician details by country.

The companies bear the costs of their own general sales forces and commercial overhead in marketing joint venture products around the world. In the U.S., Canada and Puerto Rico, the cholesterol agreements provide for a reimbursement to each company for physician details that are set on an annual basis, and in Italy, a contractual amount is included in the profit sharing calculation that is not reimbursed. In the U.S., Canada and Puerto Rico this amount is equal to each company's physician details multiplied by a contractual fixed fee. Schering-Plough reports these amounts as part of equity income from the cholesterol joint venture. These amounts do not represent a reimbursement of specific, incremental and identifiable costs for Schering-Plough's detailing of the cholesterol products in these markets. In addition, these amounts are not reflective of Schering-Plough's sales effort related to the joint venture as Schering-Plough's sales force and related costs associated with the joint venture are generally estimated to be higher.

Costs of the joint venture that the companies contractually share are a portion of manufacturing costs, specifically identified promotion costs (including direct-to-consumer advertising and direct and identifiable out-of-pocket promotion) and other agreed upon costs for specific services such as market support, market research, market expansion, a specialty sales force and physician education programs.

Certain specified research and development expenses are generally shared equally by Schering-Plough and Merck.

The allergy/asthma agreements provided for the joint development and marketing by the companies of a once-daily, fixed-combination tablet containing loratadine/montelukast. On April 25, 2008, the Merck/Schering-Plough joint venture received a not-approvable letter from the FDA for the proposed fixed combination of loratadine/montelukast. During the second quarter of 2008 the respiratory joint venture was terminated in accordance with the agreements. This action has no impact on the cholesterol joint venture. As a result of the termination of the respiratory joint venture, Schering-Plough expects to receive payments totaling \$105 million from Merck which Schering-Plough will recognize during 2008. During the three and six months ended June 30, 2008, the Merck/Schering-Plough joint venture allocated \$64 million of this amount to Schering-Plough, which is included in equity income.

The unaudited financial information below presents summarized combined financial information for the Merck/Schering-Plough cholesterol joint venture for the three and six months ended June 30, 2008 and 2007:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30,</b>		<b>June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			

Net sales	\$ 1,153	\$ 1,264	\$ 2,385	\$ 2,432
Cost of sales	51	51	104	101
Income from operations	782	889	1,636	1,685

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Amounts related to physician details, among other expenses, that are invoiced by Schering-Plough and Merck in the U.S., Canada and Puerto Rico are deducted from income from operations of the cholesterol joint venture.

Schering-Plough's share of the cholesterol joint venture's income from operations for the three and six months ended June 30, 2008 was \$436 million and \$895 million, respectively. Included in Schering-Plough's share of income from operations is income of \$64 million for the three and six months ended June 30, 2008 related to the termination of the respiratory joint venture with Merck. For the three and six months ended June 30, 2007, Schering-Plough's share of the cholesterol joint venture's income from operations were \$436 million and \$869 million, respectively. In the U.S. market, Schering-Plough receives a greater share of income from operations on the first \$300 million of annual ZETIA sales. As a result, Schering-Plough's share of the cholesterol joint venture's income from operations is generally higher in the first quarter than in subsequent quarters.

The following information provides a summary of the components of Schering-Plough's equity income from the cholesterol joint venture for the three and six months ended June 30, 2008 and 2007:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Schering-Plough's share of income from operations(a)	\$ 436	\$ 436	\$ 895	\$ 869
Contractual amounts for physician details	61	61	123	123
Elimination of intercompany profit and other, net	(4)	(7)	(8)	(14)
Total equity income from cholesterol joint venture	\$ 493	\$ 490	\$ 1,010	\$ 978

(a) Included in Schering-Plough's share of income from operations is income of \$64 million for the three and six months ended June 30, 2008 related to the termination of the respiratory joint venture with Merck.

Equity income from the joint venture excludes any profit arising from transactions between Schering-Plough and the joint venture until such time as there is an underlying profit realized by the joint venture in a transaction with a party other than Schering-Plough or Merck.

Due to the virtual nature of the cholesterol joint venture, Schering-Plough incurs substantial costs, such as selling, general and administrative costs, that are not reflected in equity income and are borne by the overall cost structure of Schering-Plough. These costs are reported on their respective line items in the Statements of Condensed Consolidated Operations and are not separately identifiable. The cholesterol agreements do not provide for any jointly owned facilities and, as such, products resulting from the joint venture are manufactured in facilities owned by either Schering-Plough or Merck.

During 2007, Schering-Plough announced that it had agreed with Merck to commence development of a single-tablet combination of ezetimibe and atorvastatin as a treatment for elevated cholesterol levels.

See Note 17, Legal, Environmental and Regulatory Matters, for discussion of the ENHANCE matter.

**6. SHARE-BASED COMPENSATION**

Schering-Plough adopted SFAS No. 123 (Revised 2004), Share-Based Payment (SFAS 123R), effective January 1, 2006. SFAS 123R requires companies to recognize compensation expense in an amount equal to the fair value of all share-based payments granted to employees. Schering-Plough elected the modified prospective transition method and therefore adjustments to prior periods were not required as a result of adopting SFAS 123R. Under this method, the provisions of SFAS 123R apply to all awards granted after the

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

date of adoption and to any unrecognized expense of awards unvested at the date of adoption based on the grant date fair value.

During the second quarter of 2008 and 2007, Schering-Plough issued its annual share-based compensation grants, including stock options and deferred stock units. A summary of the options, deferred stock units and performance-based deferred stock units granted during the three and six months ended June 30, 2008 and 2007 is as follows:

Number of Underlying Shares in Thousands	Three Months Ended June 30,				Six Months Ended June 30,			
	2008		2007		2008		2007	
	Underlying Shares	Weighted-Average Grant-Date Fair Value	Underlying Shares	Weighted-Average Grant-Date Fair Value	Underlying Shares	Weighted-Average Grant-Date Fair Value	Underlying Shares	Weighted-Average Grant-Date Fair Value
Stock options	7,747	\$ 6.00	9,792	\$ 8.11	13,584	\$ 5.35	9,974	\$ 8.11
Deferred stock units	4,613	18.87	5,358	31.43	4,708	18.49	5,483	31.43
Performance-based deferred stock units	30	16.57	22	38.77	1,064	19.35	1,397	23.12
Total Awards	12,390		15,172		19,356		16,854	

Options become exercisable in equal annual installments over a three-year period. The deferred stock units generally vest at the end of a three-year period from the date they were granted. The performance-based deferred stock units vest at the end of a three-year performance period if specific pre-established levels of performance, market conditions and service are met.

The weighted-average assumptions used in the Black-Scholes option pricing model for the three and six months ended June 30, 2008 and 2007, were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2008	2007	2008	2007
Dividend yield	1.1%	1.1%	1.1%	1.1%
Volatility	36.7%	24.8%	31.4%	24.8%
Risk-free interest rate	3.0%	4.6%	2.8%	4.6%
Expected term of options (in years)	4.5	4.5	4.5	4.5

Total compensation expense related to stock options, deferred stock units and performance-based deferred stock units for the three and six months ended June 30, 2008 was \$59 million and \$119 million, respectively. Total compensation

expense related to stock options, deferred stock units and performance-based deferred stock units for the three and six months ended June 30, 2007 was \$46 million and \$88 million, respectively.

At June 30, 2008, the total remaining unrecognized compensation cost related to the performance-based deferred stock units granted in 2008 amounted to \$18 million, which will be amortized over the weighted-average remaining requisite service period of 2.5 years. The remaining unrecognized compensation cost for the performance-based deferred stock units may vary each reporting period based on changes in the expected achievement of performance measures.

***Liability Plans***

In addition, Schering-Plough has two compensation plans that are classified as liability plans under SFAS 123R. Schering-Plough recognized expense of \$14 million and income of \$21 million related to these plans for the three and six months ended June 30, 2008, respectively. For the three and six months ended June 30, 2007, Schering-Plough recognized expenses of \$20 million and \$27 million, respectively.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**7. OTHER EXPENSE/(INCOME), NET**

The components of other expense/(income), net are as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Interest cost incurred	\$ 145	\$ 44	\$ 288	\$ 86
Less: amount capitalized on construction	(5)	(5)	(10)	(10)
Interest expense	140	39	278	76
Interest income	(17)	(86)	(39)	(167)
Foreign exchange losses/(gains)	11	(3)	7	(2)
Mark-to-market loss on fair value of foreign currency option		35		31
Other, net		(1)	(17)	
Total other expense/(income), net	\$ 134	\$ (16)	\$ 229	\$ (62)

During the six months ended June 30, 2008, Schering-Plough recognized a gain of \$17 million (\$12 million after tax) on the sale of a manufacturing site, which is included in Other, net.

In March 2007, as part of an overall risk management strategy and in consideration of various preliminary financing scenarios associated with the planned acquisition of OBS, Schering-Plough purchased a Euro-denominated currency option (derivative) for a premium of \$130 million. This derivative did not qualify for hedge accounting in accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, as amended (SFAS 133). Accordingly, the change in fair value of this derivative was recognized in the Statement of Condensed Consolidated Operations. During the three and six months ended June 30, 2007, Schering-Plough recognized mark-to-market losses of \$35 million and \$31 million, respectively, on this foreign currency option. This derivative was short-term (trading) in nature and did not hedge a specific financing or investing transaction. Accordingly, the cash impacts of this derivative were classified as operating cash flows in the Statement of Condensed Consolidated Cash Flows. This derivative was terminated during the fourth quarter of 2007.

During 2007, Schering-Plough participated in health care refinancing programs adopted by local government fiscal authorities in a major European market. During the three and six months ended June 30, 2007, Schering-Plough transferred \$12 million and \$95 million of its trade accounts receivables owned by a foreign subsidiary to third-party financial institutions without recourse. The transfer of trade accounts receivable qualified as sales of accounts receivable under SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. For the three and six months ended June 30, 2007, the transfer of these trade accounts receivable did not



have a material impact on Schering-Plough's Statement of Condensed Consolidated Operations. Cash flows from these transactions are included in the change in accounts receivable in operating activities.

## **8. INCOME TAXES**

Schering-Plough expects to report a U.S. Net Operating Loss (NOL) carryforward of approximately \$1.7 billion on its 2007 tax return, which will be available to offset future U.S. taxable income through 2027.

This U.S. NOL carryforward could be materially reduced after examination of Schering-Plough's income tax returns by the Internal Revenue Service (IRS). Schering-Plough continues to maintain a valuation allowance against its U.S. deferred tax assets, as management cannot conclude that it is more likely than not the benefit of the U.S. net deferred tax assets can be realized.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**9. RETIREMENT PLANS AND OTHER POST-RETIREMENT BENEFITS**

Schering-Plough has defined benefit pension plans covering eligible employees in the U.S. and certain foreign countries. In addition, Schering-Plough provides post-retirement medical and life insurance benefits primarily to its eligible U.S. retirees and their dependents through its post-retirement benefit plans.

The components of net pension expense were as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Service cost	\$ 55	\$ 32	\$ 108	\$ 63
Interest cost	59	31	118	62
Expected return on plan assets	(60)	(31)	(119)	(62)
Amortization, net	7	9	13	20
Settlement				2
Net pension expense	\$ 61	\$ 41	\$ 120	\$ 85

The components of other post-retirement benefits expense were as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Service cost	\$ 7	\$ 5	\$ 14	\$ 10
Interest cost	9	7	19	14
Expected return on plan assets	(3)	(3)	(6)	(6)
Amortization, net	1	1	3	2
Net other post-retirement benefits expense	\$ 14	\$ 10	\$ 30	\$ 20

For the three and six months ended June 30, 2008, Schering-Plough contributed \$48 million and \$96 million, respectively, to its retirement plans. For the three and six months ended June 30, 2007, Schering-Plough contributed \$22 million and \$39 million, respectively, to its retirement plans. Schering-Plough expects to contribute

approximately \$119 million to its retirement plans during the remainder of 2008.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**10. EARNINGS PER COMMON SHARE**

The following table reconciles the components of basic and diluted earnings per common share computations (EPS):

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30,</b>		<b>June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars and shares in millions)</b>			
EPS Numerator:				
Net income available to common shareholders	\$ 398	\$ 517	\$ 651	\$ 1,060
Add: Dilutive 2004 preferred stock dividends		22		43
Diluted EPS numerator	\$ 398	\$ 539	\$ 651	\$ 1,103
EPS Denominator:				
Weighted-average shares outstanding for basic EPS	1,624	1,494	1,623	1,491
Dilutive effect of options and deferred stock units	8	28	12	23
Dilutive effect of 2004 preferred shares		65		65
Weighted-average shares outstanding for diluted EPS	1,632	1,587	1,635	1,579

Diluted EPS for the three and six months ended June 30, 2008 is calculated based on net income available to common shareholders of \$398 million and \$651 million, respectively, and weighted-average diluted shares outstanding of 1.632 billion and 1.635 billion, respectively. For the three and six months ended June 30, 2007, Schering-Plough's 2004 mandatory convertible preferred stock was dilutive under accounting rules. As such, diluted EPS for both periods is calculated based on net income of \$539 million and \$1.103 billion, respectively, and weighted-average diluted shares outstanding of 1.587 billion and 1.579 billion, respectively.

During the third quarter of 2007, Schering-Plough's 2004 mandatory convertible preferred stock converted into 65 million common shares. These common shares are included in the weighted-average shares calculation for the periods after conversion.

For the three months ended June 30, 2008 and 2007, 65 million and 39 million, respectively, of equivalent common shares issuable under Schering-Plough's stock incentive plans were excluded from the computation of diluted EPS because their effect would have been antidilutive. For the six months ended June 30, 2008 and 2007, 53 million and 34 million, respectively, of equivalent common shares issuable under Schering-Plough's stock incentive plans were excluded from the computation of diluted EPS because their effect would have been antidilutive.

For the three and six months ended June 30, 2008, approximately 91 million common shares obtainable upon conversion of Schering-Plough's 2007 mandatory convertible preferred stock were excluded from the computation of diluted EPS because their effect would have been antidilutive. For the three and six months ended June 30, 2007,

approximately 65 million common shares obtainable upon conversion of the preferred stock were dilutive to EPS and were therefore included in the computation of diluted EPS.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**11. COMPREHENSIVE INCOME**

Comprehensive income is comprised of the following:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30,</b>		<b>June 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>			
Net income	\$ 436	\$ 539	\$ 726	\$ 1,103
Foreign currency translation adjustment	(1)	39	450	58
Change in measurement date for pension and other post-retirement liabilities				3
Mark-to-market gain on derivative instrument		35		35
Unrealized gain (loss) on investments available for sale	4	4	(5)	3
Total comprehensive income	\$ 439	\$ 617	\$ 1,171	\$ 1,202

Comprehensive income for the three and six months ended June 30, 2007 includes a mark-to-market gain of \$35 million related to a series of three interest rate swaps. The objective of the swaps was to hedge the interest rate payments to be made on future issuances of debt. As such, the swaps were designated as cash flow hedges of future interest payments, and in accordance with SFAS 133, the effective portion of the gains or losses on the hedges were reported in other comprehensive income and any ineffective portion was reported in operations. As a result of the Euro-denominated debt issuances during 2007, portions of the swaps were deemed ineffective and Schering-Plough recognized a \$7 million loss in the Statement of Consolidated Operations during the fourth quarter of 2007. The effective portion of the swaps of \$12 million was recorded in other comprehensive income during the fourth quarter of 2007 and is being recognized as interest expense over the life of the related debt. The cash flows related to these interest rate swaps were classified as operating cash flows in the Statement of Consolidated Cash Flows. As of June 30, 2008 and December 31, 2007, there were no open interest rate swaps.

**12. INVENTORIES**

Inventories consisted of the following:

	<b>June 30,</b>	<b>December 31,</b>
	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>	
Finished products	\$ 1,378	\$ 1,823
Goods in process	1,632	1,729
Raw materials and supplies	668	617

Total inventories and inventory classified in other non-current assets	\$ 3,678	\$ 4,169
--	----------	----------

The overall decrease in total inventories was primarily due to the amortization of the fair value step-up recorded as part of the OBS acquisition.

Included in Other assets (non-current) at June 30, 2008 and December 31, 2007 was \$200 million and \$96 million, respectively, of inventory not expected to be sold within one year.

### **13. GOODWILL AND OTHER INTANGIBLE ASSETS**

Goodwill at June 30, 2008 and December 31, 2007 was \$3.1 billion and \$2.9 billion, respectively. The increase at June 30, 2008 as compared to December 31, 2007 was due to foreign currency translation, partially

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

offset by a decrease of \$32 million due to adjustments to the preliminary purchase price allocation for the OBS acquisition. See Note 2, Acquisition.

The components of other intangible assets, net are as follows:

	<b>June 30, 2008</b>			<b>December 31, 2007</b>		
	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Net</b>	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Net</b>
	<b>(Dollars in millions)</b>					
Patents and licenses	\$ 4,269	\$ 262	\$ 4,007	\$ 4,050	\$ 55	\$ 3,995
Trademarks and other	3,006	121	2,885	2,851	67	2,784
Licenses and other	778	572	206	740	515	225
<b>Total other intangible assets</b>	<b>\$ 8,053</b>	<b>\$ 955</b>	<b>\$ 7,098</b>	<b>\$ 7,641</b>	<b>\$ 637</b>	<b>\$ 7,004</b>

These intangible assets are amortized on the straight-line method over their respective useful lives. The residual value of intangible assets is estimated to be zero. Amortization expense for the three months ended June 30, 2008 and 2007 was \$148 million and \$11 million, respectively, and \$291 million and \$21 million for the six months ended June 30, 2008 and 2007, respectively. Annual amortization expenses related to these intangible assets for the years 2008 to 2013 is expected to be approximately \$580 million.

**14. BORROWINGS**

Schering-Plough's outstanding borrowings at June 30, 2008 and December 31, 2007 were as follows:

	<b>June 30, 2008</b>	<b>December 31, 2007</b>
	<b>(Dollars in millions)</b>	
<i>Short-term</i>		
Commercial paper	\$ 149	\$ 149
Other short-term borrowings and current portion of long-term debt	306	310
Current portion of capital leases	1	2
<b>Total short-term borrowings and current portion of long-term debt</b>	<b>\$ 456</b>	<b>\$ 461</b>
<i>Long-term</i>		
5.00% senior unsecured Euro-denominated notes due 2010	\$ 788	\$ 736
Floating rate Euro-denominated term loan due 2012	1,419	1,619



Edgar Filing: SCHERING PLOUGH CORP - Form 10-Q

5.30% senior unsecured notes due 2013	1,247		1,247
5.375% senior unsecured Euro-denominated notes due 2014	2,362		2,205
6.00% senior unsecured notes due 2017	995		995
6.50% senior unsecured notes due 2033	1,143		1,143
6.55% senior unsecured notes due 2037	994		994
Capital leases	23		24
Other long-term borrowings	44		56
Total long-term borrowings, net of current portion	\$ 9,015	\$	9,019

The decrease in the Floating rate Euro-denominated term loan due 2012 was due to an early principal repayment of Euro 200 million (\$310 million) made in May 2008, offset by the impact of foreign currency translation. No prepayment penalty was incurred relating to this principal repayment. The other changes in

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

outstanding Euro-denominated borrowings at June 30, 2008 were due to foreign currency translation on Euro-denominated debt balances.

**15. FAIR VALUE MEASUREMENTS**

Schering-Plough's Condensed Consolidated Balance Sheet at June 30, 2008 includes the following assets and liabilities that are measured at fair value on a recurring basis:

	<b>Total Fair Value at June 30, 2008</b>	<b>Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>
	<b>(Dollars in millions)</b>			
<i>Assets</i>				
Securities held for employee compensation	\$ 141	\$ 141	\$	\$
Other	18	7	11	
<b>Total assets</b>	<b>\$ 159</b>	<b>\$ 148</b>	<b>\$ 11</b>	<b>\$</b>
<i>Liabilities</i>				
Employee compensation-related obligations	\$ 177	\$ 177	\$	\$
Other	1		1	
<b>Total liabilities</b>	<b>\$ 178</b>	<b>\$ 177</b>	<b>\$ 1</b>	<b>\$</b>

The majority of Schering-Plough's assets and liabilities measured at fair value on a recurring basis are measured using unadjusted quoted prices in active markets for identical items (Level 1) as inputs, multiplied by the number of units held at the balance sheet date. As of June 30, 2008, assets and liabilities with fair values measured using significant other observable inputs (Level 2) include measurements using quoted prices for identical items in markets that are not active and measurements using inputs that are derived principally from or corroborated by observable market data.

**16. SEGMENT DATA**

Schering-Plough has three reportable segments: Human Prescription Pharmaceuticals, Animal Health and Consumer Health Care. The segment sales and profit data that follow are consistent with Schering-Plough's current management reporting structure. The Human Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. The Animal Health segment discovers, develops, manufactures and markets animal

health products. The Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, primarily in the U.S.

## SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

*Net sales by segment:*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2008	2007	2008	2007
	(Dollars in millions)			
Human Prescription Pharmaceuticals	\$ 3,702	\$ 2,520	\$ 7,259	\$ 4,918
Animal Health	818	264	1,540	496
Consumer Health Care	401	394	778	739
Consolidated net sales	\$ 4,921	\$ 3,178	\$ 9,577	\$ 6,153

Net sales for the three and six months ended June 30, 2008 includes the net sales of OBS products acquired on November 19, 2007.

*Profit by segment:*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2008(1)	2007	2008(1)	2007
	(Dollars in millions)			
Human Prescription Pharmaceuticals	\$ 746	\$ 588	\$ 1,260	\$ 1,139
Animal Health	4	28	(82)	46
Consumer Health Care	63	95	169	207
Corporate and other(2)	(311)	(69)	(483)	(99)
Income before income taxes	\$ 502	\$ 642	\$ 864	\$ 1,293

(1) For the three months ended June 30, 2008, the Human Prescription Pharmaceuticals and the Animal Health segments' profits include expense of \$171 million and \$186 million, respectively, related to purchase accounting items from the OBS transaction. For the six months ended June 30, 2008, the Human Prescription Pharmaceuticals segment's profit and the Animal Health segment's loss includes expense of \$603 million and \$445 million, respectively, related to purchase accounting items from the OBS transaction.

(2) For the three and six months ended June 30, 2008, Corporate and other included special and acquisition related charges of \$94 million and \$117 million, respectively, related to the Productivity Transformation Program, which includes the ongoing integration of OBS (see Note 4, OBS Integration and Productivity Transformation Program, for additional information). For the three and six months ended June 30, 2007, \$11 million and \$12 million,

respectively, of acquisition related charges (integration planning) for the planned OBS acquisition is included in Corporate and other .

Schering-Plough's consolidated net sales do not include sales of VYTORIN and ZETIA, which are managed in the cholesterol joint venture with Merck, as Schering-Plough accounts for this joint venture under the equity method of accounting (see Note 5, Equity Income, for additional information). The Human Prescription Pharmaceuticals segment includes equity income from the Merck/Schering-Plough joint venture.

Corporate and other includes interest income and expense, foreign exchange gains and losses, currency option gains, headquarters expenses, special and acquisition-related charges and other miscellaneous items. The accounting policies used for segment reporting are the same as those described in Note 1, Summary of Significant Accounting Policies, in Schering-Plough's 2007 10-K/A.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Sales of products comprising 10 percent or more of Schering-Plough's U.S. or international sales for the three and six months ended June 30, 2008, were as follows:

	<b>Three Months Ended June 30, 2008</b>		<b>Six Months Ended June 30, 2008</b>	
	<b>Amount (Dollars in millions)</b>	<b>Percentage of Applicable Sales (%)</b>	<b>Amount (Dollars in millions)</b>	<b>Percentage of Applicable Sales (%)</b>
<b>U.S.</b>				
NASONEX	\$ 166	12	\$ 338	12
<b>International</b>				
REMICADE	557	16	1,064	16

For the three and six months ended June 30, 2008, net sales outside the U.S. totaled \$3.5 billion and \$6.7 billion, respectively. This approximated 70 percent of consolidated net sales for both periods.

Schering-Plough does not disaggregate assets on a segment basis for internal management reporting and, therefore, such information is not presented.

## **17. LEGAL, ENVIRONMENTAL AND REGULATORY MATTERS**

### ***Background***

Schering-Plough is involved in various claims, investigations and legal proceedings.

Schering-Plough records a liability for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. Schering-Plough adjusts its liabilities for contingencies to reflect the current best estimate of probable loss or minimum liability, as the case may be. Where no best estimate is determinable, Schering-Plough records the minimum amount within the most probable range of its liability. Expected insurance recoveries have not been considered in determining the amounts of recorded liabilities for environmental related matters.

If Schering-Plough believes that a loss contingency is reasonably possible, rather than probable, or the amount of loss cannot be estimated, no liability is recorded. However, where a liability is reasonably possible, disclosure of the loss contingency is made.

Schering-Plough reviews the status of all claims, investigations and legal proceedings on an ongoing basis, including related insurance coverages. From time to time, Schering-Plough may settle or otherwise resolve these matters on terms and conditions management believes are in the best interests of Schering-Plough. Resolution of any or all claims, investigations and legal proceedings, individually or in the aggregate, could have a material adverse effect on

Schering-Plough's consolidated results of operations, cash flows or financial condition.

Except for the matters discussed in the remainder of this Note, the recorded liabilities for contingencies at June 30, 2008, and the related expenses incurred during the three and six months ended June 30, 2008, were not material. In the opinion of management, based on the advice of legal counsel, the ultimate outcome of these matters, except matters discussed in the remainder of this Note, will not have a material impact on Schering-Plough's consolidated results of operations, cash flows or financial condition.

***ENHANCE Matter***

In early 2008, the Merck / Schering-Plough cholesterol joint venture announced the results of the ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) clinical trial. Schering-Plough encountered a challenge affecting sales of ZETIA and VYTORIN when the results of the ENHANCE

## SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

trial, as well as the length of time that expired between the last patient having an ultrasound image taken for the trial through the final analysis and the unblinding of data, became the subjects of intense scrutiny and varying interpretations in the media.

Schering-Plough, the joint venture and/or its joint venture partner, Merck, have received a number of governmental inquiries and have been the subject of a number of investigations with respect to the timing and disclosures relating to the ENHANCE clinical trial, the trial results, and in some cases sales of stock by the companies' officers prior to release of the results of the ENHANCE clinical trial. Since mid-January 2008, Schering-Plough has become aware of or been served with litigation relating to such matters.

Schering-Plough is cooperating fully with the various investigations and responding to the requests for information, and Schering-Plough intends to vigorously defend the lawsuits that have been filed relating to these matters.

Earlier this year, after the initial release of ENHANCE data, the FDA stated that it would review the results of the trial, which may take approximately six months.

Please refer to "Legal Proceedings" in Item 3 in Schering-Plough's 2007 10-K/A and Part II, Item 1, "Legal Proceedings," in this 10-Q for additional information. Also see Part II, OTHER INFORMATION, "Recent Cholesterol Clinical Trials," for information about another clinical trial relating to VYTORIN, SEAS.

#### *AWP Litigation and Investigations*

Schering-Plough continues to respond to existing and new litigation by certain states and private payors and investigations by the Department of Health and Human Services, the Department of Justice and several states into industry and Schering-Plough practices regarding average wholesale price (AWP). Schering-Plough is cooperating with these investigations.

These litigations and investigations relate to whether the AWP used by pharmaceutical companies for certain drugs improperly exceeds the average prices paid by providers and, as a consequence, results in unlawful inflation of certain reimbursements for drugs by state programs and private payors that are based on AWP. The complaints allege violations of federal and state law, including fraud, Medicaid fraud and consumer protection violations, among other claims. In the majority of cases, the plaintiffs are seeking class certifications. In some cases, classes have been certified. The outcome of these litigations and investigations could include substantial damages, the imposition of substantial fines, penalties and injunctive or administrative remedies.

#### *Securities and Class Action Litigation*

##### *Federal Securities Litigation*

Following Schering-Plough's announcement that the FDA had been conducting inspections of Schering-Plough's manufacturing facilities in New Jersey and Puerto Rico and had issued reports citing deficiencies concerning compliance with current Good Manufacturing Practices, several lawsuits were filed against Schering-Plough and certain named officers. These lawsuits allege that the defendants violated the federal securities law by allegedly failing to disclose material information and making material misstatements. Specifically, they allege that Schering-Plough



failed to disclose an alleged serious risk that a new drug application for CLARINEX would be delayed as a result of these manufacturing issues, and they allege that Schering-Plough failed to disclose the alleged depth and severity of its manufacturing issues. These complaints were consolidated into one action in the U.S. District Court for the District of New Jersey, and a consolidated amended complaint was filed on October 11, 2001, purporting to represent a class of shareholders who purchased shares of Schering-Plough stock from May 9, 2000 through February 15, 2001. The complaint seeks compensatory damages on behalf of the class. The Court certified the shareholder class on October 10, 2003.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Notice of pendency of the class action was sent to members of that class in July 2007. Discovery has been completed, and motions for summary judgment have been briefed and are pending.

*ERISA Litigation*

On March 31, 2003, Schering-Plough was served with a putative class action complaint filed in the U.S. District Court in New Jersey alleging that Schering-Plough, retired Chairman, CEO and President Richard Jay Kogan, Schering-Plough's Employee Savings Plan (Plan) administrator, several current and former directors, and certain former corporate officers breached their fiduciary obligations to certain participants in the Plan. The complaint seeks damages in the amount of losses allegedly suffered by the Plan. The complaint was dismissed on June 29, 2004. The plaintiffs appealed. On August 19, 2005 the U.S. Court of Appeals for the Third Circuit reversed the dismissal by the District Court and the matter has been remanded back to the District Court for further proceedings.

*K-DUR Antitrust Litigation*

Schering-Plough had settled patent litigation with Upsher-Smith, Inc. (Upsher-Smith) and ESI Lederle, Inc. (Lederle) relating to generic versions of K-DUR, Schering-Plough's long-acting potassium chloride product supplement used by cardiac patients, for which Lederle and Upsher Smith had filed Abbreviated New Drug Applications. Following the commencement of an FTC administrative proceeding alleging anti-competitive effects from those settlements (which has been resolved in Schering-Plough's favor), alleged class action suits were filed in federal and state courts on behalf of direct and indirect purchasers of K-DUR against Schering-Plough, Upsher-Smith and Lederle. These suits claim violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. These suits seek unspecified damages. Discovery is ongoing.

*Third-Party Payor Actions*

Several purported class action litigations have been filed following the announcement of the settlement of the Massachusetts Investigation. Plaintiffs in these actions seek damages on behalf of third-party payors resulting from the allegations of off-label promotion and improper payments to physicians that were at issue in the Massachusetts Investigation.

*Tax Matters*

In October 2001, IRS auditors asserted that two interest rate swaps that Schering-Plough entered into with an unrelated party should be recharacterized as loans from affiliated companies, resulting in additional tax liability for the 1991 and 1992 tax years. In September 2004, Schering-Plough made payments to the IRS in the amount of \$194 million for income tax and \$279 million for interest. Schering-Plough filed refund claims for the tax and interest with the IRS in December 2004. Following the IRS's denial of Schering-Plough's claims for a refund, Schering-Plough filed suit in May 2005 in the U.S. District Court for the District of New Jersey for refund of the full amount of the tax and interest. This refund litigation has been tried in Newark District Court and a decision has not yet been rendered. Schering-Plough's tax reserves were adequate to cover the above-mentioned payments.

*Pending Administrative Obligations*

In connection with the settlement of an investigation with the U.S. Department of Justice and the U.S. Attorney's Office for the Eastern District of Pennsylvania, Schering-Plough entered into a five-year corporate integrity agreement (CIA). The CIA was amended in August of 2006 in connection with the settlement of the Massachusetts Investigation, commencing a new five-year term. Failure to comply with the obligations under the CIA could result in financial penalties.

**SCHERING-PLOUGH CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

***Other Matters***

***Product Liability***

Beginning in May of 2007, a number of complaints have been filed in various jurisdictions asserting claims against Organon USA, Inc., Organon Pharmaceuticals USA, Inc., and/or Organon International ( Organon ) arising from Organon s marketing and sale of NUVARING, a combined hormonal contraceptive vaginal ring. The plaintiffs contend that Organon failed to adequately warn of the alleged increased risk of venous thromboembolism ( VTE ) posed by NUVARING, and/or downplayed the risk of VTE. The plaintiffs seek damages for injuries allegedly sustained from their product use, including some alleged deaths, heart attacks and strokes. The majority of the cases are currently pending in the United States District Court for the District of New Jersey. Other cases are pending in Wisconsin, Missouri, New York and Georgia.

***French Matter***

Based on a complaint to the French competition authority from a competitor in France and pursuant to a court order, the French competition authority has obtained documents from a French subsidiary of Schering-Plough relating to SUBUTEX, one of the products that the subsidiary markets and sells. Any resolution of this matter adverse to the French subsidiary could result in the imposition of civil fines and injunctive or administrative remedies. On July 17, 2007, the Juge des Libertés et de la Détention ordered the annulment of the search and seizure on procedural grounds. On July 19, 2007, the French authority appealed the order to the French Supreme Court.

In April 2007, the competitor also requested interim relief, a portion of which was granted by the French competition authority in December 2007. The interim relief required Schering-Plough s French subsidiary to publish in two specialized newspapers information including that the generic has the same quantitative and qualitative composition and the same pharmaceutical form as, and is substitutable for, SUBUTEX. In February 2008, the Paris Court of Appeal confirmed the decision of the French competition authority.

***Environmental***

Schering-Plough has responsibilities for environmental cleanup under various state, local and federal laws, including the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund. At several Superfund sites (or equivalent sites under state law), Schering-Plough is alleged to be a potentially responsible party (PRP). Schering-Plough believes that it is remote at this time that there is any material liability in relation to such sites. Schering-Plough estimates its obligations for cleanup costs for Superfund sites based on information obtained from the federal Environmental Protection Agency (EPA), an equivalent state agency and/or studies prepared by independent engineers, and on the probable costs to be paid by other PRPs. Schering-Plough records a liability for environmental assessments and/or cleanup when it is probable that a loss has been incurred and the amount can be reasonably estimated.

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Shareholders of Schering-Plough Corporation

We have reviewed the accompanying condensed consolidated balance sheet of Schering-Plough Corporation and subsidiaries (the Company) as of June 30, 2008, and the related statements of condensed consolidated operations for the three and six-month periods ended June 30, 2008 and 2007, and the statements of condensed consolidated cash flows for the six-month periods ended June 30, 2008 and 2007. These interim financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to such condensed consolidated interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of the Company as of December 31, 2007, and the related statements of consolidated operations, shareholders' equity, and cash flows for the year then ended (not presented herein); and in our report dated February 29, 2008, we expressed an unqualified opinion on those consolidated financial statements and included an explanatory paragraph regarding the Company's adoption of Statement of Financial Accounting Standards (SFAS) No. 123 (Revised 2004), *Share-Based Payment*, SFAS No. 158, *Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans*, and Financial Accounting Standards Board Interpretation No. 48, *Accounting for Uncertainty in Income Taxes*. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2007 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Deloitte & Touche LLP

Parsippany, New Jersey  
July 31, 2008

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

### **EXECUTIVE OVERVIEW**

#### ***Overview of Schering-Plough***

Schering-Plough is an innovation-driven science-centered global health care company. Schering-Plough discovers, develops and manufactures pharmaceuticals for three customer markets – human prescription, animal health and consumer. While most of the research and development activity is directed toward human prescription products, there are important applications of this central research and development platform into the animal health products and the consumer health care products. Schering-Plough also accesses external innovation via partnering, in-licensing and acquisition for all three customer markets.

#### ***Strategy Focused on Science***

In 2003, soon after Fred Hassan was elected as Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation, he initiated a six-to-eight year strategic plan, called the Action Agenda. A key component of the Action Agenda is applying science to meet unmet medical needs. A core strategy of Schering-Plough is to invest substantial funds in scientific research with the goal of creating therapies and treatments that address important unmet medical needs and also have commercial value. Consistent with this core strategy, Schering-Plough is increasing its investment in research and development. Schering-Plough has been successful in advancing the pipeline and has several late-stage projects that will require sizable resources to complete. As Schering-Plough continues to develop the later-phase pipeline compounds (e.g., golimumab, sugammadex, thrombin receptor antagonist, vicriviroc, boceprevir and asenapine), it anticipates higher spending on clinical trial activities. Schering-Plough's progressing early pipeline includes drug candidates across a wide range of therapeutic areas.

Another key component of the Action Agenda is the focus on building long-term value for shareholders and for the patients who rely upon Schering-Plough's drugs. This longer-term focus includes concurrent emphasis on growing sales, disciplined cost controls and investing in research and development for the future.

Early on, Hassan and the new management team that he recruited applied the Action Agenda to stabilizing, repairing and turning around Schering-Plough after Schering-Plough encountered challenges earlier this decade under a prior management team.

Currently, Schering-Plough continues work in the fourth of five phases of the Action Agenda. During the fourth, or Build the Base phase, Schering-Plough continues to focus on its strategy of value creation across a broad front. Over the past four years, sales of Schering-Plough pharmaceutical products across an array of therapeutic areas showed strong growth compared to prior periods and other pharmaceutical companies. Schering-Plough's pharmaceutical sales and marketing activities expanded geographically, including into Brazil, China and Russia. This geographic diversity adds to growth and makes performance less sensitive to any one geographic area. The strategic Organon BioSciences N.V. (OBS) acquisition was closed in November 2007 and significant integration activities continue. The OBS acquisition added further diversification of marketed products, including two new therapeutic areas (Women's Health and Central Nervous System); key pipeline projects; significant strength in the Animal Health products and pipeline; and significant talent, including in key research and development functions.

As part of the Action Agenda, Schering-Plough continues to work to enhance infrastructure, upgrade processes and systems and strengthen talent. While these efforts are being implemented on a companywide basis, Schering-Plough is focusing especially on research and development to support Schering-Plough's science-based business.

The pharmaceutical industry is under increasing political and regulatory pressure, particularly in the United States and Schering-Plough and the Merck/Schering-Plough cholesterol joint venture have encountered specific challenges during 2008, as explained in more detail in Part II, OTHER INFORMATION, Recent Cholesterol Clinical Trials.

The strength Schering-Plough built during the earlier phases of the Action Agenda, including the diversified group of products, customer segments, and geographic areas, as well as its highly experienced executive team, will be helpful in weathering current and future challenges, including those relating to the Merck/Schering-Plough cholesterol joint venture.

Regarding challenges in regard to the recent cholesterol clinical trials, Schering-Plough's strategy is centered on emphasizing the science around high LDL cholesterol (low-density lipoprotein, often known as "bad cholesterol"), which medical experts and health advisory groups have long recognized as a significant cardiovascular risk factor and recommended increasingly aggressive treatment of high cholesterol for certain patients. Lowering LDL cholesterol, along with a healthy diet and lifestyle changes, remains the cornerstone of lipid treatment for patients at risk for heart disease. Clinical studies have demonstrated that VYTORIN lowers patients' LDL cholesterol more than rosuvastatin, atorvastatin and simvastatin at the doses studied and was able to get more patients to the LDL cholesterol goals identified by the National Cholesterol Education Program, Adult Treatment Panel III (ATP III) guidelines. The ENHANCE and Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) clinical trials also demonstrated superior LDL cholesterol lowering with VYTORIN compared to simvastatin (ENHANCE) and placebo (SEAS). See Outlook for the current perspective on the effects of these challenges on Schering-Plough's business.

In April 2008, Schering-Plough announced the Productivity Transformation Program (PTP). The goal of this program, which includes the ongoing integration of OBS, is to create a leaner, stronger company to support Schering-Plough's goal of building long-term high performance despite the current challenging pharmaceutical industry environment and the particular challenges facing Schering-Plough. This program targets savings of \$1.5 billion on an annualized basis by 2012 and is designed to reduce and avoid costs, while increasing productivity. Of the total targeted savings, approximately \$1.25 billion are anticipated to be accomplished by the end of 2010 with the balance achieved by 2012. The targeted savings envisioned by this program include those resulting from the previously announced OBS integration synergies. Beyond this program, Schering-Plough anticipates investing in new high priority clinical trials, the pursuit of strategic opportunities, including product launches and anticipates natural cost growth. Approximately 1,100 positions have been eliminated through June 30, 2008.

***Results and Highlights for the three and six months ended June 30, 2008:***

Schering-Plough's net sales for the three months ended June 30, 2008 were \$4.9 billion, an increase of \$1.7 billion, or 55 percent, as compared to the three months ended June 30, 2007. The increase was primarily due to the contribution of the OBS businesses during 2008. Net income available to common shareholders for the three months ended June 30, 2008 was \$398 million, as compared to \$517 million in the three months ended June 30, 2007.

Schering-Plough's net sales for the six months ended June 30, 2008 were \$9.6 billion, an increase of \$3.4 billion, or 56 percent, as compared to the six months ended June 30, 2007. The increase was primarily due to the contribution of the OBS businesses during 2008. Net income available to common shareholders for the six months ended June 30, 2008 was \$651 million, as compared to \$1.1 billion in the six months ended June 30, 2007.

For the three and six months ended June 30, 2008, net sales outside the U.S. totaled \$3.5 billion and \$6.7 billion, respectively. This approximated 70 percent of consolidated net sales for both periods.

Increased sales in the six months ended June 30, 2008, of pharmaceutical products such as REMICADE and TEMODAR as well as increased sales in the Animal Health segment contributed favorably to Schering-Plough's overall operating results.



Global combined net sales of Schering-Plough's cholesterol franchise products, VYTORIN and ZETIA, managed by the cholesterol joint venture with Merck & Company, Inc. (Merck) decreased 2 percent during the first six months of 2008 as compared to the first six months of 2007. Combined net sales of the products VYTORIN and ZETIA in the U.S. decreased 16 percent during the first six months of 2008 as compared to the first six months of 2007.

## Strategic Alliances

As is typical in the pharmaceutical industry, Schering-Plough licenses manufacturing, marketing and/or distribution rights to certain products to others, and also manufactures, markets and/or distributes products owned by others pursuant to licensing and joint venture arrangements. Any time that third parties are involved, there are additional factors relating to the third party and outside the control of Schering-Plough that may create positive or negative impacts on Schering-Plough. VYTORIN, ZETIA and REMICADE are subject to such arrangements and are key to Schering-Plough's current business and financial performance.

In addition, any potential strategic alternatives may be impacted by the change of control provisions in those arrangements, which could result in VYTORIN and ZETIA being acquired by Merck or REMICADE reverting back to Centocor. The change in control provision relating to VYTORIN and ZETIA is included in the contract with Merck, filed as Exhibit 10(r) to Schering-Plough's 2007 10-K/A, and the change of control provision relating to REMICADE is contained in the contract with Centocor, filed as Exhibit 10(v) to Schering-Plough's 2007 10-K/A.

## Cholesterol Franchise

Schering-Plough's cholesterol franchise products, VYTORIN and ZETIA, are managed through a joint venture between Schering-Plough and Merck for the treatment of elevated cholesterol levels in all markets outside Japan. ZETIA is Schering-Plough's novel cholesterol absorption inhibitor. VYTORIN is the combination of ZETIA and Zocor (simvastatin), a statin medication developed by Merck. The financial commitment to compete in the cholesterol reduction market is shared with Merck, and profits from the sales of VYTORIN and ZETIA are also shared with Merck. The operating results of the joint venture with Merck are recorded using the equity method of accounting.

The cholesterol-reduction market is the single largest pharmaceutical category in the world. VYTORIN and ZETIA are competing in this market. Global total combined sales of VYTORIN and ZETIA for the three and six months ended June 30, 2008, decreased 10 percent and 2 percent, respectively, as compared to the three and six months ended June 30, 2007. During the three and six months ended June 30, 2008, total combined sales of VYTORIN and ZETIA outside the U.S. increased 37 percent and 41 percent, respectively, as compared to the three and six months ended June 30, 2007. During the three and six months ended June 30, 2008, total combined sales of VYTORIN and ZETIA in the U.S. declined 26 percent and 16 percent, respectively, as compared to the three and six months ended June 30, 2007. As of June 2008, total combined prescription share for VYTORIN and ZETIA in the U.S. was down approximately five market share points versus December 2007 from 16.9 percent to 12.1 percent. Media reaction to the release of the results of the ENHANCE clinical trial in early 2008 led some commentators to call for the use of other products, rather than VYTORIN and ZETIA. Continued reductions in the sales and/or market share of Schering-Plough's cholesterol franchise would have a significant impact on Schering-Plough's consolidated results of operations and cash flows. In the past, Schering-Plough's profitability has been largely dependent upon the performance of the cholesterol franchise; while performance of the cholesterol franchise is still material to Schering-Plough, as the product diversity has become stronger (through the OBS acquisition as well as development of other Schering-Plough products) the dependence on the cholesterol franchise is lessening.

Japan is not included in the joint venture with Merck. In the Japanese market, Bayer Healthcare is co-marketing Schering-Plough's cholesterol-absorption inhibitor, ZETIA, which was approved in Japan in April 2007 as a monotherapy and co-administered with a statin for use in patients with hypercholesterolemia, familial hypercholesterolemia or homozygous sitosterolemia. ZETIA was launched in Japan during June 2007. Schering-Plough's sales of ZETIA in Japan under the co-marketing agreement with Bayer Healthcare are recognized in net sales.

**License Arrangements with Centocor**

REMICADE is prescribed for the treatment of inflammatory diseases such as rheumatoid arthritis, early rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis and ulcerative colitis.

REMICADE is Schering-Plough's second largest marketed pharmaceutical product line (after the

cholesterol franchise). REMICADE is licensed from and manufactured by Centocor, Inc., a Johnson & Johnson company. During 2005, Schering-Plough exercised an option under its contract with Centocor for license rights to develop and commercialize golimumab, a fully human monoclonal antibody which has been filed for approval in Europe. Schering-Plough has exclusive marketing rights to both products outside the U.S., Japan and certain Asian markets. In December 2007, Schering-Plough and Centocor revised their distribution agreement regarding the development, commercialization and distribution of both REMICADE and golimumab, extending Schering-Plough's rights to exclusively market REMICADE to match the duration of Schering-Plough's exclusive marketing rights for golimumab. Effective upon regulatory approval of golimumab in the EU, Schering-Plough's marketing rights for both products will now extend for 15 years after the first commercial sale of golimumab within the EU. Centocor will receive a progressively increased share of profits on Schering-Plough's distribution of both products in the Schering-Plough marketing territory between 2010 and 2014, and the share of profits will remain fixed thereafter for the remainder of the term. The changes to the duration of REMICADE marketing rights and the profit sharing arrangement for the products are all conditioned on approval of golimumab being granted prior to September 1, 2014. Schering-Plough may independently develop and market golimumab for a Crohn's disease indication in its territories, with an option for Centocor to participate. In addition, Schering-Plough and Centocor agreed to utilize an autoinjector device in the commercialization of golimumab and further agreed to share its development costs.

### **Manufacturing, Sales and Marketing**

Schering-Plough supports commercialized products with manufacturing, sales and marketing efforts. Schering-Plough is also moving forward with additional investments to enhance its infrastructure and business, including capital expenditures for the drug development process (where products are moved from the drug discovery pipeline to markets), information technology systems, and post-marketing studies and monitoring.

Schering-Plough continually reviews the business, including manufacturing operations, to identify actions that will enhance long-term competitiveness. However, Schering-Plough's manufacturing cost base is relatively fixed, and actions to significantly reduce Schering-Plough's manufacturing infrastructure, including specific reviews of Schering-Plough's manufacturing operations that will be made as part of PTP involve complex issues. As a result, shifting products between manufacturing plants can take many years due to construction and regulatory requirements, including revalidation and registration requirements. Future events and decisions may lead to asset impairments or related costs.

### ***Regulatory and Competitive Environment***

Schering-Plough is subject to the jurisdiction of various national, state and local regulatory agencies. Regulatory compliance is complex and costly, impacting the timing needed to bring new drugs to market and to market drugs for new indications.

Schering-Plough engages in clinical trial research in many countries around the world. Research activities must comply with stringent regulatory standards and are subject to inspection by the U.S., the EU, and local country regulatory authorities. Schering-Plough is subject to pharmacovigilance reporting requirements in many countries and other jurisdictions, including the U.S., the EU, and the EU member states. Clinical trials and post-marketing surveillance of certain marketed drugs of competitors within the industry have raised safety concerns that have led to recalls, withdrawals or adverse labeling of marketed products.

A number of intermediaries are involved between drug manufacturers, such as Schering-Plough, and patients who use the drugs. These intermediaries impact the patient's ability, and their prescribers' ability, to choose and pay for a particular drug. These intermediaries include health care providers, such as hospitals and clinics; payors and their representatives, such as employers, insurers, managed care organizations and governments; and others in the supply

chain, such as pharmacists and wholesalers. Further, in the U.S., many of Schering-Plough's pharmaceutical products are subject to increasingly competitive pricing as certain of the intermediaries (including managed care groups, institutions and government agencies) seek price discounts. In most international markets, Schering-Plough operates in an environment of government-mandated cost-containment programs. Also, the pricing, sales and marketing programs and arrangements, and related business

practices of Schering-Plough and other participants in the health care industry are under continued scrutiny from federal and state regulatory, investigative, prosecutorial and administrative entities.

The market for pharmaceutical products is competitive. Schering-Plough's operations may be affected by technological advances of competitors, industry consolidation, patents granted to competitors, loss of patent protection due to challenges by competitors, competitive combination products, new products of competitors, new information from clinical trials of marketed products or post-marketing surveillance and generic competition as Schering-Plough's products mature.

### **OBS Acquisition**

On November 19, 2007, Schering-Plough acquired OBS for a purchase price of approximately Euro 11 billion in cash, or approximately \$16.1 billion.

Commencing from the acquisition date, OBS's assets acquired and liabilities assumed, as well as the results of OBS operations, are included in Schering-Plough's consolidated financial statements.

The impact of purchase accounting, based on a preliminary valuation, resulted in the following non-cash pre-tax items during the three and six months ended June 30, 2008:

Amortization of inventory adjusted to fair value, which totaled approximately \$1.1 billion, will be charged to cost of sales over an approximate one-year period from the acquisition date (\$211 million and \$762 million for the three and six months ended June 30, 2008, respectively).

Amortization of acquired intangible assets adjusted to fair value, which totaled \$6.8 billion will be amortized over a weighted-average life of 15 years to cost of sales (\$138 million and \$270 million for the three and six months ended June 30, 2008, respectively).

Incremental depreciation relating to the adjustment in fair value on property, plant and equipment of \$896 million that will be depreciated over the lives of the applicable plant and equipment primarily to cost of sales (\$8 million and \$16 million for the three and six months ended June 30, 2008, respectively).

### **DISCUSSION OF OPERATING RESULTS**

The results of operations for the three and six months ended June 30, 2008 discussed below include OBS's product sales and expenses as well as certain non-cash items relating to purchase accounting associated with the OBS acquisition.

#### ***Net Sales***

A significant portion of net sales is made to major pharmaceutical and health care product distributors and major retail chains in the U.S. Consequently, net sales and quarterly growth comparisons may be affected by fluctuations in the buying patterns of major distributors, retail chains and other trade buyers. These fluctuations may result from seasonality; pricing; wholesaler, retail and trade buying decisions; changes in overall demand factors or other factors. In addition to these fluctuations, sales of many pharmaceutical products in the U.S. are subject to increased pricing pressure from managed care groups, institutions, government agencies, and other groups seeking discounts. Schering-Plough and other pharmaceutical manufacturers in the U.S. market are also required to provide statutorily defined rebates to various government agencies in order to participate in the Medicaid program, veterans' health care programs and other government-funded programs. The Medicare Prescription Drug Improvement and Modernization Act of 2003 contains a prescription drug benefit for individuals who are eligible for Medicare and has resulted in

increased use of generics and increased purchasing power of those negotiating on behalf of Medicare recipients. In most international markets, Schering-Plough operates in an environment where governments have mandated cost-containment programs, placed restrictions on physician prescription levels and patient reimbursements, emphasized greater use of generic drugs and enacted across-the-board price cuts as methods to control costs.

Consolidated net sales for the three months ended June 30, 2008 totaled \$4.9 billion, an increase of \$1.7 billion or 55 percent compared with the same period in 2007, including an estimated impact of 7.6 percent from foreign exchange on stand-alone Schering-Plough net sales. For the six months ended June 30, 2008, consolidated net sales totaled \$9.6 billion, an increase of \$3.4 billion or 56 percent as compared to the same period in 2007, including an estimated impact of 7.4 percent from foreign exchange on stand-alone Schering-Plough net sales. The impact of currency is more pronounced on products and businesses that are concentrated in Europe.

Consolidated net sales for the three and six months ended June 30, 2008 included \$1.4 billion and \$2.8 billion of net sales of OBS products. The increase in net sales also reflects the growth in sales volumes of REMICADE and TEMODAR as well as Animal Health and Consumer Health Care products.

For the three and six months ended June 30, 2008, net sales outside the U.S. totaled \$3.5 billion and \$6.7 billion, respectively. Net sales outside the U.S. approximated 70 percent of consolidated net sales for both periods.

Net sales for the three and six months ended June 30, 2008 and 2007 were as follows:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2008 (Dollars in millions)	2007	Increase (Decrease) (%)	2008 (Dollars in millions)	2007	Increase (Decrease) (%)
<b>PRESCRIPTION PHARMACEUTICALS</b>	<b>\$ 3,702</b>	<b>\$ 2,520</b>	<b>47%</b>	<b>\$ 7,259</b>	<b>\$ 4,918</b>	<b>48%</b>
REMICADE	557	394	41%	1,064	767	39%
NASONEX	311	295	6%	618	579	7%
TEMODAR	251	216	16%	487	412	18%
CLARINEX/AERIUS	240	250	(4%)	454	455	
PEGINTRON	229	234	(2%)	454	451	1%
FOLLISTIM/PUREGON	162			308		
NUVARING	116			212		
CLARITIN Rx	111	102	8%	239	214	11%
INTEGRILIN	78	78		152	163	(7%)
CAELYX	78	65	20%	152	127	20%
REBETOL	70	74	(5%)	130	146	(11%)
ZEMURON	67			130		
AVELOX	67	75	(12%)	209	191	10%
REMERON	61			129		
Other Pharmaceutical	1,304	737	77%	2,521	1,413	78%
<b>ANIMAL HEALTH</b>	<b>818</b>	<b>264</b>	<b>210%</b>	<b>1,540</b>	<b>496</b>	<b>211%</b>
<b>CONSUMER HEALTH CARE</b>	<b>401</b>	<b>394</b>	<b>2%</b>	<b>778</b>	<b>739</b>	<b>5%</b>
OTC	181	182	(1%)	389	359	8%
OTC CLARITIN	120	137	(12%)	258	264	(2%)
MIRALAX	28	6	N/M	54	14	N/M
Other OTC	33	39	(16%)	77	81	(5%)
Foot Care	105	102	3%	190	180	5%



Edgar Filing: SCHERING PLOUGH CORP - Form 10-Q

Sun Care	115	110	5%	199	200	(1%)
<b>CONSOLIDATED NET SALES</b>	<b>\$ 4,921</b>	<b>\$ 3,178</b>	<b>55%</b>	<b>\$ 9,577</b>	<b>\$ 6,153</b>	<b>56%</b>

N/M Not a meaningful percentage.

Sales of Human Prescription Pharmaceuticals in the second quarter of 2008 totaled \$3.7 billion, a \$1.2 billion or 47 percent increase as compared to the second quarter of 2007. Included in the second quarter of 2008 was \$921 million of net sales related to the prescription pharmaceutical sales of OBS. Excluding sales of OBS prescription pharmaceuticals, net sales of Human Prescription Pharmaceuticals declined 7 percent in the U.S in the second quarter.

Sales of Human Prescription Pharmaceuticals for the six months ended June 30, 2008 totaled \$7.3 billion, a \$2.3 billion or 48 percent increase as compared to the six months ended June 30, 2007. Included in the six month sales amounts in 2008 was \$1.8 billion of net sales related to the prescription pharmaceutical sales of OBS. Excluding sales of OBS prescription pharmaceuticals, net sales of Human Prescription Pharmaceuticals declined 5 percent in the U.S in the six months ended June 30, 2008.

International net sales of REMICADE, for the treatment of immune-mediated inflammatory disorders such as rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis, were up \$163 million or 41 percent to \$557 million in the second quarter of 2008 and \$297 million or 39 percent to \$1.1 billion for the first six months of 2008, driven by continued market growth, expanded use and a favorable impact from foreign exchange. Competitive products for the indications referred to above were introduced during 2007 and 2008.

Global net sales of NASONEX Nasal Spray, an inhaled nasal corticosteroid for allergies, rose \$16 million or 6 percent to \$311 million in the second quarter of 2008 and \$39 million or 7 percent to \$618 million for the first six months of 2008, due to increased sales in international markets, partially offset by a decline in sales in the United States. Competitive products were introduced in 2007 and 2008.

Global net sales of TEMODAR Capsules, a treatment for certain types of brain tumors, increased \$35 million or 16 percent to \$251 million in the second quarter of 2008 and \$75 million or 18 percent to \$487 million for the first six months of 2008 due to increased demand across most geographic regions.

Global net sales of CLARINEX (marketed as AERIUS in many countries outside the U.S.), a non-sedating antihistamine for the treatment of seasonal outdoor allergies and year-round indoor allergies, decreased 4 percent to \$240 million in the second quarter of 2008 and decreased \$1 million to \$454 million for the first six months of 2008 primarily due to lower sales in the United States.

Global net sales of PEGINTRON, for treating hepatitis C, decreased 2 percent to \$229 million in the second quarter of 2008. For the first six months of 2008, PEGINTRON increased 1 percent to \$454 million due to higher sales in Latin America, emerging markets across Europe and a favorable impact from foreign exchange, tempered by lower sales in Japan and the U.S.

Global net sales of FOLLISTIM/PUREGON, a recombinant follicle-stimulating hormone for treating infertility, were \$162 million in the second quarter of 2008 and \$308 million for the six months ended June 30, 2008. FOLLISTIM/PUREGON was obtained as part of the OBS acquisition.

Global net sales of NUVARING, a contraception product, were \$116 million in the second quarter of 2008 and \$212 million for the six months ended June 30, 2008. NUVARING was obtained as part of the OBS acquisition.

International net sales of prescription CLARITIN increased 8 percent to \$111 million in the second quarter of 2008 and increased 11 percent to \$239 million for the first six months of 2008, as a result of favorable foreign exchange and increased sales in Japan.

Global net sales of INTEGRILIN Injection, a glycoprotein platelet aggregation inhibitor for the treatment of patients with acute coronary syndrome, which is sold primarily in the U.S. by Schering-Plough, was \$78 million for both the second quarter of 2008 and 2007. Global net sales of INTEGRILIN decreased 7 percent to \$152 million for the first six months of 2008 due to a decrease in U.S. market size.

International net sales of CAELYX, for the treatment of ovarian cancer, metastatic breast cancer and Kaposi's sarcoma, increased 20 percent to \$78 million in the second quarter of 2008 and 20 percent to \$152 million for the first six months of 2008, due to higher sales across Europe.

Global net sales of REBETOL Capsules, for use in combination with PEGINTRON or INTRON A for treating hepatitis C, decreased 5 percent to \$70 million in the second quarter of 2008 and 11 percent to \$130 million in the first six months of 2008 due to continued lower sales in Japan.

Global net sales of ZEMURON, a muscle relaxant used in surgical procedures, were \$67 million in the second quarter of 2008 and \$130 million in the first six months of 2008. ZEMURON was obtained as part of the OBS acquisition. ZEMURON will lose patent exclusivity in the U.S. in 2008 and in the EU in 2009.

Net sales of AVELOX, a fluoroquinolone antibiotic for the treatment of certain respiratory and skin infections, sold primarily in the U.S. by Schering-Plough as a result of its license agreement with Bayer, decreased 12 percent to \$67 million in the second quarter of 2008 primarily reflecting a weaker respiratory tract infection season. Net sales of AVELOX for the first six months of 2008 increased 10 percent to \$209 million primarily as a result of increased market share tempered by market decline.

Global net sales of REMERON, an antidepressant, were \$61 million in the second quarter of 2008 and \$129 million in the first six months of 2008. REMERON was obtained as part of the OBS acquisition.

Other pharmaceutical net sales include a large number of lower sales volume prescription pharmaceutical products and included \$515 million and \$1.0 billion of net sales of the human health segment of OBS for the second quarter and the first six months of 2008, respectively. Several of these products are sold in limited markets outside the U.S., and many are multiple source products no longer protected by patents. These products include treatments for respiratory, cardiovascular, dermatological, infectious, oncological and other diseases.

Global net sales of Animal Health products increased 210 percent in the second quarter of 2008 to \$818 million and 211 percent to \$1.5 billion for the first six months of 2008. Included in global Animal Health net sales was \$526 million and \$980 million of the animal health segment of OBS for the second quarter of 2008 and the first six months of 2008, respectively. Sales benefited from solid growth in all geographic regions, including in Europe where Schering-Plough recently launched a vaccine for bluetongue disease (Bovilis BTV8). Bluetongue disease is a devastating disease of cattle and sheep caused by a virus which was first identified in Northern Europe in 2006. The newly combined animal health organization also achieved sales growth in products for cattle and poultry. Animal Health sales also benefited from foreign exchange. The Animal Health segment's sales growth rate is impacted by intense competition and frequent introductions of generic products. In April 2008, Schering-Plough announced the planned divestiture of certain animal health products in connection with conditions set forth by the European Commission as part of the acquisition of Intervet. Net sales of the planned divested products have not been material.

Global net sales of Consumer Health Care products, which include OTC, foot care and sun care products, increased 2 percent to \$401 million in the second quarter of 2008. The increase in the second quarter of 2008 was mainly due to higher sales of MiraLAX, which was launched in February 2007 as the first Rx-to-OTC switch in the laxative category in more than 30 years, partially offset by lower sales of OTC CLARITIN, due to a less severe allergy season and increased competition. Global net sales of Consumer Health Care products for the first six months of 2008 increased 5 percent to \$778 million. This growth was primarily due to sales of MiraLAX and foot care products partially offset by lower sales of OTC CLARITIN. OTC CLARITIN will continue to face competition from a cetirizine allergy product and other store brands. Future sales in the Consumer Health Care segment are difficult to predict because the consumer health care market is highly competitive, with heavy advertising to consumers and frequent competitive product introductions.



**Costs, Expenses and Equity Income**

A summary of costs, expenses and equity income for the three and six months ended June 30, 2007 and 2006 is as follows:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2008 (Dollars in millions)	2007	Increase (Decrease) %	2008 (Dollars in millions)	2007	Increase (Decrease) %
Gross margin	61.2%	69.3%	(8.1%)	57.8%	68.9%	(11.1%)
Selling, general and administrative (SG&A)	\$ 1,870	\$ 1,358	38%	\$ 3,547	\$ 2,572	38%
Research and development (R&D)	906	696	30%	1,786	1,403	27%
Other expense/(income), net	134	(16)	N/M	229	(62)	N/M
Special and acquisition related charges	94	11	N/M	117	12	N/M
Equity income from cholesterol joint venture	(493)	(490)	1%	(1,010)	(978)	3%

N/M Not a meaningful percentage.

Substantially all the sales of cholesterol products are not included in Schering-Plough's net sales. The results of these sales are reflected in equity income from cholesterol joint venture. In addition, due to the virtual nature of the joint venture, Schering-Plough incurs substantial selling, general and administrative expenses that are not captured in equity income but are included in Schering-Plough's Statements of Consolidated Operations. As a result, Schering-Plough's gross margin, and ratios of SG&A expenses and R&D expenses as a percentage of net sales do not reflect the benefit of the impact of the joint venture's operating results.

**Gross margin**

Gross margin decreased to 61.2 percent in the second quarter of 2008 and 57.8 percent for the first six months of 2008 as compared to 69.3 percent and 68.9 percent for the second quarter and first six months of 2007, respectively. Gross margin for the three and six months ended June 30, 2008 was unfavorably impacted by \$354 million and \$1.0 billion, respectively, of purchase accounting items included in cost of sales. These purchase accounting items resulted from the amortization of fair values of certain assets acquired as part of the OBS acquisition.

**Selling, general and administrative**

Selling, general and administrative expenses (SG&A) were \$1.9 billion in the second quarter of 2008 and \$3.5 billion in the first six months of 2008, up 38 percent versus both prior year periods. These increases in SG&A are primarily due to the inclusion of OBS expenses and the impact of foreign exchange.

**Research and development**

Research and development (R&D) spending increased 30 percent to \$906 million in the second quarter of 2008 and 27 percent to \$1.8 billion in the first six months of 2008. Included in R&D for the three and six months ended June 30, 2008 is approximately \$235 million and \$460 million, respectively, from OBS. R&D spending in the second quarter and first six months of 2007 included \$60 million and \$156 million, respectively, related to upfront payments made for licensing transactions. The increase in R&D spending versus 2007 also reflects higher spending for clinical trials and related activities and investments to build greater breadth and capacity to support the continued expansion of Schering-Plough's pipeline. Generally, changes in R&D spending reflect the timing of Schering-Plough's funding of both internal research efforts and research collaborations with various partners to discover and develop a steady flow of innovative products.

To maximize its chances for the successful development of new products, Schering-Plough began a Development Excellence initiative in 2005 to build talent and critical mass, create a uniform level of

excellence and deliver on high-priority programs within R&D. In 2006, Schering-Plough began a Global Clinical Harmonization Program to maximize and globalize the quality of clinical trial execution, pharmacovigilance and regulatory processes. Beginning in 2007, certain aspects of the Global Clinical Harmonization Program have been implemented and are being integrated into the processes of OBS.

*Other expense/( income), net*

Schering-Plough had \$134 million and \$229 million of other expense, net, for the three and six months ended June 30, 2008, respectively, as compared to \$16 million and \$62 million of other income, net, for the three and six months ended June 30, 2007, respectively. Other expense, net, for the three and six months ended June 30, 2008 reflected higher interest expense due to the issuance of new debt in connection with the acquisition of OBS in the second half of 2007. The decrease in interest income was due to the use of existing cash for the acquisition of OBS. Other income, net, for the second quarter and first six months of 2007 reflected higher interest income due to higher interest rates on cash equivalents and short-term investments and lower interest expense due to lower short-term borrowing levels partially offset by losses of \$35 million and \$31 million, respectively, on the mark-to-market of a foreign currency option.

*Special and acquisition-related charges*

Special and acquisition-related charges relate to PTP activities which include the ongoing integration of the OBS business. Special and acquisition-related charges for the three and six months ended June 30, 2008 were \$94 million and \$117 million, respectively. The costs for the three and six months ended June 30, 2008 included \$77 million and \$84 million, respectively, of employee termination costs. For the three and six months ended June 30, 2007, special and acquisition-related charges were \$11 million and \$12 million, respectively.

The following table summarizes the charges, cash payments and liabilities related to employee termination costs through June 30, 2008, excluding purchase accounting items:

	<b>Employee Termination Costs(a) (Dollars in millions)</b>	
Accrued liability at December 31, 2007	\$	23(b)
Charges		84
Cash payments		(27)
Accrued liability at June 30, 2008	\$	80

(a) Recorded to special and acquisition-related charges.

(b) Represents employee termination costs recorded under SFAS No. 112, Employers Accounting for Postemployment Benefits, in the fourth quarter of 2007.

*Equity income*



Sales of the Merck/Schering-Plough cholesterol joint venture for the three and six months ended June 30, 2008 totaled \$1.2 billion and \$2.4 billion, respectively, as compared to \$1.3 billion and \$2.4 billion for the three and six months ended June 30, 2007.

The companies bear the costs of their own general sales forces and commercial overhead in marketing joint venture products around the world. In the U.S., Canada and Puerto Rico, the cholesterol agreements provide for a reimbursement to each company for physician details that are set on an annual basis, and in Italy, a contractual amount is included in the profit sharing calculation that is not reimbursed. In the U.S., Canada and Puerto Rico, this amount is equal to each company's physician details multiplied by a contractual fixed fee. Schering-Plough reports these amounts as part of equity income from the cholesterol joint venture. These amounts do not represent a reimbursement of specific, incremental and identifiable costs for Schering-

Plough's detailing of the cholesterol products in these markets. In addition, these amounts are not reflective of Schering-Plough's sales effort related to the joint venture, as Schering-Plough's sales force and related costs associated with the joint venture are generally estimated to be higher.

Costs of the joint venture that the companies contractually share are a portion of manufacturing costs, specifically identified promotion costs (including direct-to-consumer advertising and direct and identifiable out-of-pocket promotion) and other agreed upon costs for specific services such as market support, market research, market expansion, a specialty sales force and physician education programs.

Certain specified research and development expenses are generally shared equally by Schering-Plough and Merck.

The allergy/asthma agreements provided for the joint development and marketing by the companies of a once-daily, fixed-combination tablet containing loratadine/montelukast. On April 25, 2008, the Merck/Schering-Plough joint venture received a not-approvable letter from the FDA for the proposed fixed combination of loratadine/montelukast. During the second quarter of 2008 the respiratory joint venture was terminated in accordance with the agreements. This action has no impact on the cholesterol joint venture. As a result of the termination of the respiratory joint venture, Schering-Plough expects to receive payments totaling \$105 million from Merck which Schering-Plough will recognize during 2008. During the three and six months ended June 30, 2008, the Merck/Schering-Plough joint venture allocated \$64 million of this amount to Schering-Plough, which is included in equity income.

Equity income from the Merck/Schering-Plough cholesterol joint venture totaled \$493 million and \$1.0 billion for the three and six months ended June 30, 2008, respectively, as compared to \$490 million and \$978 million for the three and six months ended June 30, 2007, respectively. The increase in 2008 equity income amounts compared to 2007 reflects income of \$64 million related to the termination of the respiratory joint venture. Equity income also reflects sales declines of VYTORIN and ZETIA in the U.S. partially offset by sales growth internationally.

It should be noted that Schering-Plough incurs substantial selling, general and administrative and other costs, which are not reflected in equity income from the cholesterol joint venture and instead are included in the overall cost structure of Schering-Plough.

#### *Provision for income taxes*

Tax expense was \$66 million and \$138 million for the three and six months ended June 30, 2008, respectively. Tax expense was \$103 million and \$190 million for the three and six months ended June 30, 2007, respectively. The tax provision for the three and six months ended June 30, 2008 included tax benefits of \$54 million and \$142 million, respectively, primarily related to the amortization of fair values of certain assets acquired as part of the OBS acquisition. The income tax expense primarily relates to foreign taxes and does not include any benefit related to U.S. operating losses.

Schering-Plough expects to report a U.S. Net Operating Loss (NOL) carryforward of approximately \$1.7 billion on its 2007 tax return, which will be available to offset future U.S. taxable income through 2027. This U.S. NOL carryforward could be materially reduced after examination of Schering-Plough's income tax returns by the Internal Revenue Service (IRS). Schering-Plough continues to maintain a valuation allowance against its U.S. deferred tax assets, as management cannot conclude that it is more likely than not the benefit of the U.S. net deferred tax assets can be realized.

**LIQUIDITY AND FINANCIAL RESOURCES***Discussion of Cash Flow*

	<b>Six Months Ended June 30, 2008      2007 (Dollars in millions)</b>	
Cash flow provided by operating activities	\$ 1,384	\$ 628
Cash flow (used for)/provided by investing activities	(329)	1,598
Cash flow used for financing activities	(649)	(57)

*Operating Activities*

In the first six months of 2008, operating activities provided \$1.4 billion of cash, compared with net cash provided by operations of \$628 million in the first six months of 2007. The increase is primarily due to the absence of special and acquisition-related payments associated with the settlement of the Massachusetts Investigation in 2007 and the purchase of a currency option related to the acquisition of OBS. The increase also reflects the inclusion of the OBS business.

*Investing Activities*

Net cash used for investing activities during the first six months of 2008 was \$329 million and primarily relates to capital expenditures. Net cash provided by investing activities for the first six months of 2007 was \$1.6 billion due primarily to maturities of short-term investments.

*Financing Activities*

Net cash used for financing activities was \$649 million for the first six months of 2008, compared to \$57 million for the same period in 2007. Uses of cash for financing activities for the six months ended June 30, 2008 included the pay down of Euro-denominated long term debt of Euro 200 million (\$310 million) and payment of dividends on common and preferred shares of \$286 million. Net cash used for financing activities for the six months ended June 30, 2007 included dividends on common and preferred shares of \$222 million partially offset by \$177 million of proceeds from stock option exercises.

*Other Discussion of Cash Flows*

At June 30, 2008, Schering-Plough had net debt (total debt less cash, cash equivalents and short-term investments) of approximately \$6.7 billion. Cash generated from operations and available cash and short-term investments are expected to provide Schering-Plough with the ability to fund cash needs for the intermediate term.

In July 2007, Schering-Plough made a cash payment of \$98 million for tax and interest due in connection with an examination by the IRS of Schering-Plough's 1997-2002 federal income tax returns.

*Borrowings and Credit Facilities*

At June 30, 2008 and December 31, 2007, short-term borrowings and current maturities of short-term debt totaled \$456 million and \$461 million, respectively, including outstanding commercial paper of \$149 million at June 30, 2008 and December 31, 2007.

Total debt at June 30, 2008 was \$9.5 billion, consistent with the total debt balance at December 31, 2007. Total debt includes Euro-denominated notes and a Euro-denominated term loan. An early principal repayment of Euro 200 million (\$310 million) in May 2008 resulted in a decrease in the Floating rate Euro-denominated term loan due 2012. There was no prepayment penalty associated with this principal payment. The reduction in the total debt balance related to the pay down in the Euro-denominated term loan was offset by the impact of foreign exchange on the Euro-denominated bank debt and bonds.

Schering-Plough has a \$2.0 billion credit facility with a syndicate of banks available for general corporate purposes. This facility has a floating interest rate, matures in August 2012 and is used primarily to support Schering-Plough's commercial paper borrowings. As of June 30, 2008, no borrowings were outstanding under this facility.

Schering-Plough's current unsecured senior credit ratings and ratings review status are as follows:

<b>Senior Unsecured Credit Ratings</b>	<b>Long-Term</b>	<b>Short-Term</b>	<b>Long-Term Review Status</b>
Moody's Investors Service	Baa1	P-2	Negative Outlook
Standard and Poor's	A-	A-2	Negative Watch
Fitch Ratings	BBB+	F-2	Negative Watch

The short-term ratings discussed above have not significantly affected Schering-Plough's ability to issue debt or rollover its outstanding commercial paper borrowings at this time. However, Schering-Plough believes the ability of commercial paper issuers, such as Schering-Plough, with one or more short-term credit ratings of P-2 from Moody's, A-2 from S&P and/or F-2 from Fitch to issue or rollover outstanding commercial paper can, at times, be less than that of companies with higher short-term credit ratings. In addition, the total amount of commercial paper capacity available to these issuers is typically less than that of higher-rated companies. Schering-Plough's sizable lines of credit with commercial banks as well as cash and short-term investments held by U.S. and international subsidiaries serve as alternative sources of liquidity and to support its commercial paper program.

### ***Contractual Obligations***

Schering-Plough's contractual obligations as of December 31, 2007 were included in tabular format in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, of the 2007 10-K/A.

Payments due by period for interest payment obligations on Schering-Plough's debt as of December 31, 2007 are as follows: less than one year, \$550 million; one to three years, \$1.0 billion; three to five years, \$924 million; more than five years, \$3.8 billion.

Potential milestone payments of \$2.3 billion were not included in the contractual obligations table as they are contingent on the achievement of various research and development (approximately \$600 million), regulatory approval (approximately \$700 million) or sales-based (approximately \$1.0 billion) milestones. Research, development and regulatory milestones depend upon future clinical developments as well as regulatory agency actions which may never occur. Sales-based milestones are contingent on generating levels of sales of current or future products that have not yet been achieved.

### **REGULATORY AND COMPETITIVE ENVIRONMENT IN WHICH SCHERING-PLOUGH OPERATES**

Schering-Plough is subject to the jurisdiction of various national, state and local regulatory agencies. The regulations to which Schering-Plough is subject are described in more detail in Part I, Item I, Business, of Schering-Plough's 2007 10-K/A. Regulatory compliance is complex, as regulatory standards (including Good Clinical Practices, Good Laboratory Practices and Good Manufacturing Practices) vary by jurisdiction and are constantly evolving. Regulatory compliance is also costly. Regulatory compliance also impacts the timing needed to bring new drugs to market and to market drugs for new indications. Further, failure to comply with regulations can result in delays in the approval of drugs, seizure or recall of drugs, suspension or revocation of the authority necessary for the production and sale of drugs, fines and other civil or criminal sanctions.

Regulatory compliance, and the cost of compliance failures, can have a material impact on Schering-Plough's results of operations, its cash flows or financial condition.

Much is still unknown about the science of human health and with every drug there are benefits and risks. Societal and government pressures are constantly shifting between the demand for innovation to meet

urgent unmet medical needs and adversity to risk. These pressures impact the regulatory environment and the market for Schering-Plough's products.

### ***Regulatory Compliance and Pharmacovigilance***

#### ***Regulatory Inspections***

Schering-Plough is subject to pharmacovigilance reporting requirements in many countries and other jurisdictions, including the U.S., the EU, and the EU member states. The requirements differ from jurisdiction to jurisdiction, but all include requirements for reporting adverse events that occur while a patient is using a particular drug in order to alert the drug's manufacturer and the governmental agency to potential problems.

During 2003, pharmacovigilance inspections by officials of the British and French medicines agencies conducted at the request of the European Medicines Agency (EMA) cited serious deficiencies in reporting processes. Schering-Plough has continued to work on its long-term action plan to rectify the deficiencies and has provided regular updates to the EMA.

During the fourth quarter of 2005, local UK and EMA regulatory authorities conducted a follow-up inspection to assess Schering-Plough's implementation of its action plan. In the first quarter of 2006, these authorities also inspected the U.S.-based components of Schering-Plough's pharmacovigilance system. The inspectors acknowledged that progress had been made since 2003, but also continued to note significant concerns with the quality systems supporting Schering-Plough's pharmacovigilance processes. Similarly, in a follow-up inspection of Schering-Plough's clinical trial practices in the UK, inspectors identified issues with respect to Schering-Plough's management of clinical trials and related pharmacovigilance practices.

In February 2006, Schering-Plough began the Global Clinical Harmonization Program for building clinical excellence (in trial design, execution and tracking), which will strengthen Schering-Plough's scientific and compliance rigor on a global basis. In 2007, certain aspects of the Global Clinical Harmonization Program were implemented, and work is continuing in 2008 and is expected to continue for several years. In addition, during the fourth quarter of 2007, the local UK regulatory authority conducted a follow-up inspection which confirmed that the corrective actions committed to by Schering-Plough following the 2006 inspection of Schering-Plough's UK-based clinical trial operations had in fact been completed. In early January 2008, the local UK regulatory authority returned for a follow-up inspection of Schering-Plough's UK pharmacovigilance operations. This inspection likewise confirmed that a number of corrective actions had been completed since the last inspection and noted the number of actions Schering-Plough had taken as set forth in Schering-Plough's periodic updates to the EMA and noted a limited number of observations that Schering-Plough is addressing. Schering-Plough intends to continue upgrading skills, processes and systems in clinical practices and pharmacovigilance. Schering-Plough remains committed to accomplish this work and to invest significant resources in this area.

Schering-Plough does not know what action, if any, the EMA or national authorities will take in response to the inspections. Possible actions include further inspections, demands for improvements in reporting systems, criminal sanctions against Schering-Plough and/or responsible individuals and changes in the conditions of marketing authorizations for Schering-Plough's products.

### ***Regulatory Compliance and Post-Marketing Surveillance***

Schering-Plough engages in clinical trial research in many countries around the world. These clinical trial research activities must comply with stringent regulatory standards and are subject to inspection by U.S., EU and local country regulatory authorities. Failure to comply with current Good Clinical Practices or other applicable laws or regulations

can result in delays in approval of clinical trials, suspension of ongoing clinical trials, delays in approval of marketing authorizations, criminal sanctions against Schering-Plough and/or responsible individuals, and changes in the conditions of marketing authorizations for Schering-Plough's products.

Clinical trials and post-marketing surveillance of certain marketed drugs of competitors within the industry have raised safety concerns that have led to recalls, withdrawals or adverse labeling of marketed



products. In addition, these situations have raised concerns among some prescribers and patients relating to the safety and efficacy of pharmaceutical products in general. For the past several years, these occurrences have increased. Recently the intense media attention to the results of the ENHANCE clinical trial led to some concerns among patients and prescribers about ZETIA and VYTORIN (see discussion under "Strategy-Focused on Science" in the Executive Overview).

Following this wave of product withdrawals by other companies and other significant safety issues, health authorities such as the FDA, the EMEA and the PMDA have continued to increase their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications and are re-reviewing select products that are already marketed, adding further to the uncertainties in the regulatory processes. There is also greater regulatory scrutiny, especially in the U.S., on advertising and promotion and in particular direct-to-consumer advertising.

Similarly, major health authorities, including the FDA, EMEA and PMDA, have also increased collaboration amongst themselves, especially with regard to the evaluation of safety and benefit/risk information. Media attention has also increased. In the current environment, a health authority regulatory action in one market, such as a safety labeling change, may have regulatory, prescribing and marketing implications in other markets to an extent not previously seen.

Some health authorities, such as the PMDA in Japan, have publicly acknowledged a significant backlog in workload due to resource constraints within their agency. This backlog has caused long regulatory review times for new indications and products and has added to the uncertainty in predicting approval timelines in these markets. While the PMDA has committed to correcting the backlog and has made some progress over the last year, it is expected to continue for the foreseeable future.

These and other uncertainties inherent in government regulatory approval processes, including, among other things, delays in approval of new products, formulations or indications, may also affect Schering-Plough's operations. The effect of regulatory approval processes on operations cannot be predicted.

Schering-Plough has nevertheless achieved a significant number of important regulatory approvals since 2004, including approvals for VYTORIN, Sugammadex (in Europe), NOXAFIL, CLARINEX D-24, CLARINEX REDITABS, CLARINEX D-12, SUBOXONE and new indications for TEMODAR and NASONEX. Other significant approvals since 2004 include ASMANEX DPI (Dry Powder for Inhalation) in the U.S., PEGINTRON, ZETIA, TEMODAR, ESMERON/ESLAX, NASONEX and GANIREST in Japan, and new indications for REMICADE. Schering-Plough also has a number of significant regulatory submissions filed in major markets awaiting approval.

Schering-Plough's personnel have regular, open dialogue with the FDA and other regulators and review product labels and other materials on a regular basis and as new information becomes known.

### ***Pricing Pressures***

As described more specifically in Note 17, "Legal, Environmental and Regulatory Matters," under Item 1, "Financial Statements," the pricing, sales and marketing programs and arrangements, and related business practices of Schering-Plough and other participants in the health care industry are under increasing scrutiny from federal and state regulatory, investigative, prosecutorial and administrative entities. These entities include the Department of Justice and its U.S. Attorney's Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission (FTC) and various state Attorneys General offices. Many of the health care laws under which certain of these governmental entities operate, including the federal and state anti-kickback statutes and statutory and common law false claims laws, have been construed broadly by the courts and permit the government

entities to exercise significant discretion. In the event that any of those governmental entities believes that wrongdoing has occurred, one or more of them could institute civil or criminal proceedings, which, if instituted and resolved unfavorably, could subject Schering-Plough to substantial fines, penalties and injunctive or administrative remedies, including exclusion from government reimbursement programs. Schering-Plough also cannot predict whether any investigations

will affect its marketing practices or sales. Any such result could have a material adverse impact on Schering-Plough's results of operations, cash flows, financial condition, or its business.

In the U.S., many of Schering-Plough's pharmaceutical products are subject to increasingly competitive pricing as managed care groups, institutions, government agencies and other groups seek price discounts. In the U.S. market, Schering-Plough and other pharmaceutical manufacturers are required to provide statutorily defined rebates to various government agencies in order to participate in Medicaid, the veterans health care program and other government-funded programs. The Medicare Prescription Drug Improvement and Modernization Act of 2003 contains a prescription drug benefit for individuals who are eligible for Medicare and has resulted in increased use of generics and increased purchasing power of those negotiating on behalf of Medicare recipients.

In most international markets, Schering-Plough operates in an environment of government mandated cost-containment programs. Several governments have placed restrictions on physician prescription levels and patient reimbursements; emphasized greater use of generic drugs; and enacted across-the-board price cuts as methods to control costs.

Since Schering-Plough is unable to predict the final form and timing of any future domestic or international governmental or other health care initiatives, including the passage of laws permitting the importation of pharmaceuticals into the U.S., their effect on operations and cash flows cannot be reasonably estimated. Similarly, the effect on operations and cash flows of decisions of government entities, managed care groups and other groups concerning formularies and pharmaceutical reimbursement policies cannot be reasonably estimated.

### ***Competition***

The market for pharmaceutical products is competitive. Schering-Plough's operations may be affected by technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, new information from clinical trials of marketed products or post-marketing surveillance and generic competition as Schering-Plough's products mature. In addition, patent positions are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products. The effect on operations of competitive factors and patent disputes cannot be predicted.

### **OUTLOOK**

Schering-Plough does not provide numeric guidance. However, the following outlook may be helpful to readers in assessing future prospects.

See Part II, OTHER INFORMATION, Recent Cholesterol Clinical Trials. Given the current uncertainties in the cholesterol markets, it is difficult to predict the long-term performance of the cholesterol franchise. Currently, Schering-Plough anticipates that net sales by the Merck/Schering-Plough cholesterol joint venture of VYTORIN and ZETIA in the U.S. will decline on a year-over-year basis in the second half of 2008. Further, wholesalers, retail chains and other trade buyers in the U.S. have changed their buying patterns to reduce their inventory levels, and may make further changes, that may also impact future sales. Based on the expectation of lower U.S. sales from the Merck/Schering-Plough cholesterol joint venture, Schering-Plough expects that equity income will be lower in the second half of 2008 than it was in the first half of 2008.

Schering-Plough expects R&D spending to be higher in the second half of 2008 than it was in the first half of 2008.

The risks set forth in Part II, Item 1A, Risk Factors, of this 10-Q could cause actual results to differ materially from the expectation provided in this section.



**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

Refer to Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, in Schering-Plough's 2007 10-K/A for disclosures regarding Schering-Plough's critical accounting policies and estimates.

Schering-Plough's rebate accruals for federal and state governmental programs, including Medicaid and Medicare Part D, at June 30, 2008 and 2007 were \$125 million and \$122 million, respectively. Commercial discounts, returns and other rebate accruals at June 30, 2008 and 2007 were \$422 million and \$377 million, respectively. These accruals are established in the period that the related revenue was recognized, resulting in a reduction to sales and the establishment of liabilities, which are included in total current liabilities, or in the case of returns and other receivable adjustments, an allowance provided against accounts receivable.

The following summarizes the activity in the accounts related to accrued rebates, sales returns and discounts for the six months ended June 30, 2008 and 2007:

	<b>2008</b>	<b>2007</b>
	<b>(Dollars in millions)</b>	
Accrued rebates/returns/discounts, beginning of period	\$ 526	\$ 486
Provision for rebates	365	298
Adjustment to prior-year estimates	(3)	(17)
Payments	(339)	(257)
	23	24
Provision for returns	92	94
Purchase-accounting adjustments(1)	(9)	
Adjustment to prior-year estimates	(4)	(23)
Returns	(61)	(57)
	18	14
Provision for discounts	440	349
Adjustment to prior-year estimates	(5)	
Discounts granted	(455)	(374)
	(20)	(25)
Accrued rebates/returns/discounts, end of period	\$ 547	\$ 499

(1) For the six months ended June 30, 2008, purchase-accounting adjustments include \$9 million related to the reversal of return reserves recorded as part of the purchase accounting for OBS. This reversal was recorded as a reduction to goodwill.

In formulating and recording the above accruals, management utilizes assumptions and estimates that include historical experience, wholesaler data, the projection of market conditions, the estimated lag time between sale and payment of a rebate, utilization estimates, and forecasted product demand amounts.

As part of its review of these accruals, management performs a sensitivity analysis that considers differing assumptions, which are most subject to judgment in its rebate accrual calculation. Based upon Schering-Plough's sensitivity analysis, reasonably possible changes to assumptions related to rebate accruals could favorably or unfavorably impact 2008 net sales and income before income taxes in an annual amount of \$20 million.

## DISCLOSURE NOTICE

### *Cautionary Statements Under the Private Securities Litigation Reform Act of 1995*

Management's Discussion and Analysis of Financial Condition and Results of Operations and other sections of this report, as well as other written reports and oral statements made from time to time by Schering-Plough, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as anticipate, believe, could, estimate, expect, forecast, project, intend, plan, potential, will, and similar words. In particular, forward-looking statements include statements relating to Schering-Plough's plans; its strategies; timing and level of savings achieved from the Productivity Transformation Program, including the ongoing integration of OBS; prospective products or product approvals; actions to enhance clinical, research and development, manufacturing and post-marketing systems; the potential of products and trending in therapeutic markets, including the cholesterol market; patent and other intellectual property protection; future performance or results of current and anticipated products; research and development programs and anticipated spending; estimates of rebates, discounts and returns; and the outcome of contingencies such as litigation and investigations.

Any or all forward-looking statements here or in other publications may turn out to be wrong. There are no guarantees about Schering-Plough's financial and operational performance or the performance of Schering-Plough's stock. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. Although it is not possible to predict or identify all such factors, we refer you to Part II, Item 1A, "Risk Factors," of this 10-Q for identification of important factors with respect to risks and uncertainties.

### **Item 3. *Quantitative and Qualitative Disclosures about Market Risk***

Schering-Plough is exposed to market risk primarily from changes in foreign currency exchange rates and, to a lesser extent, from interest rates and equity prices. The impact of currency is more pronounced on products and businesses that are concentrated in Europe.

Refer to Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," in Schering-Plough's 2007 10-K/A for further discussion of market risks.

### **Item 4. *Controls and Procedures***

Management, including the chief executive officer and the chief financial officer, has evaluated Schering-Plough's disclosure controls and procedures as of the end of the quarterly period covered by this 10-Q and has concluded that Schering-Plough's disclosure controls and procedures are effective. They also concluded that there were no changes in Schering-Plough's internal control over financial reporting that occurred during Schering-Plough's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, Schering-Plough's internal control over financial reporting.

Schering-Plough is replacing and upgrading a number of information systems, and commencing in the first quarter of 2008, integrating the Organon BioSciences N.V. human and animal health businesses. The overall process will be ongoing for several years. In connection with these changes, as part of Schering-Plough's management evaluation of both internal control over financial reporting and disclosure controls and procedures, management has concluded that the new processes are at least as effective with respect to those controls as the prior processes. An example of a

change in process that occurred during the first six months of 2008 is the integration of the OBS human health U.S. procure-to-pay process into the Schering-Plough U.S. procure-to-pay system.



## PART II. OTHER INFORMATION

### Recent Cholesterol Clinical Trials

*SEAS Clinical Trial.* On July 21, 2008, preliminary results of the Merck/Schering-Plough cholesterol joint venture's SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) clinical trial, in which VYTORIN was studied for a new potential use, its effect on patients with aortic stenosis, and no evidence of cardiovascular disease, were released to the public. The results showed that, although VYTORIN reduced LDL-cholesterol by an average of 61% compared to placebo; there was no significant difference between VYTORIN and placebo on the primary endpoint which was a combination of the occurrence of aortic valve replacement surgery and major cardiovascular events. Currently, valve replacement surgery is the treatment of choice for aortic stenosis. However, the results did show VYTORIN was significantly more effective than placebo in reducing the incidence of atherosclerotic events. In addition, although VYTORIN was generally well tolerated by patients in the clinical trial, there was an imbalance in the occurrence of cancer between the treatment and placebo arms, with a higher incidence and a higher number of cancer deaths in the VYTORIN arm.

Because the cancer data from the SEAS clinical trial involve only 158 patients, the higher cancer incidence may be a result of chance and not attributable to VYTORIN. Accordingly, to better understand the possible implications of these unexpected cancer data, the University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) performed an independent analysis of the combined cancer results from two other, ongoing studies involving VYTORIN. The SHARP (Study of Heart and Renal Protection) clinical trial, is a randomized, placebo-controlled trial of VYTORIN in 9,400 patients with chronic kidney disease. The other clinical trial, IMPROVE-IT (Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin), is a randomized, double-blind trial of VYTORIN compared to simvastatin alone in patients with acute coronary disease. Currently, there are 12,000 patients enrolled in the IMPROVE-IT clinical trial, with a total planned enrollment of 18,000. The SEAS clinical trial, by contrast, included 1,873 patients. CTSU worked independently of Schering-Plough, Merck and the Merck/Schering-Plough cholesterol joint venture to perform the analysis.

CTSU found that in the SHARP and IMPROVE-IT clinical trials, there was not the cancer imbalance observed in the SEAS clinical trial. Cancers in the SHARP and IMPROVE-IT clinical trials were distributed equally across all treatment arms and showed no clustering of any cancer type. The cancers observed in the SEAS clinical trial were also not clustered, that is they were distributed across all major organ systems. Also, the incidence of cancers was consistent with the rates that would be expected based upon data from Scandinavian age-adjusted cancer registries. Further, there was no year-by-year increase in cancer rates as would be expected where a compound increases cancer risk. Having reviewed all of the available data, the CTSU concluded that the SEAS, SHARP, and IMPROVE-IT clinical trials do not provide credible evidence of any adverse effect on cancer. Schering-Plough believes the cancer finding in SEAS is likely to be an anomaly that, taken in light of all the available data, does not support an association with VYTORIN. Schering-Plough, through the Merck/Schering-Plough cholesterol joint venture, is committed to working with regulatory agencies to further evaluate the available data and interpretations of those data; however, Schering-Plough does not believe that changes in the clinical use of VYTORIN are warranted.

See Part II, Item 1, Legal Proceedings below regarding the ENHANCE clinical trial.

### Item 1. *Legal Proceedings*

Material pending legal proceedings involving Schering-Plough are described in Part I, Item 3, Legal Proceedings, of the 2007 10-K/A. The following discussion is limited to material developments to previously reported proceedings and new material legal proceedings, which Schering-Plough, or any of its subsidiaries, became a party during the

quarter ended June 30, 2008, or subsequent thereto, but before the filing of this report. This section should be read in conjunction with Part I, Item 3, Legal Proceedings in the 2007 10-K/A.

***ENHANCE Matter***

*Background.* The Merck/Schering-Plough cholesterol joint venture markets ZETIA and VYTORIN (a combination of Merck's Zocor (simvastatin) and Schering-Plough's Zetia (ezetimibe)).

The Merck/Schering-Plough cholesterol joint venture's ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) clinical trial was a surrogate endpoint trial, conducted in 720 patients with Heterozygous Familial Hypercholesterolemia, a rare condition that affects approximately 0.2% of the population. The primary endpoint was the mean change in the intima-media thickness measured at three sites in the carotid arteries (the right and left common carotid, internal carotid and carotid bulb) between patients treated with ezetimibe/simvastatin 10/80 mg versus patients treated with simvastatin 80 mg alone over a two-year period. There was no statistically significant difference between the treatment groups for the primary endpoint or for each of the components of the primary endpoint, including the common carotid artery. Key secondary imaging endpoints also showed no statistical difference between treatment groups.

Technical difficulties consumed a long time period after the last patient was scanned in April 2006 until December 31, 2007, when data from ultrasound images were first unblinded to scientists of the Merck/Schering-Plough cholesterol joint venture. After analysis of the results, the summary findings were released by the joint venture on January 14, 2008 and full results were released later in the first quarter 2008. There has been significant media attention to the length of time between the last patient having an ultrasound taken for the trial through the final analysis and the unblinding of the data, and to the trial results. In addition, these issues have been raised in private lawsuits against Schering-Plough, as well as in investigations that are ongoing. These events impacted sales, as discussed in Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.

Medical experts and health advisory groups have long recognized high LDL cholesterol as a significant cardiovascular risk factor and recommended increasingly aggressive treatment of high cholesterol for certain patients. Lowering LDL cholesterol, along with healthy diet and lifestyle changes, remains the cornerstone of lipid treatment for patients at risk for heart disease.

Clinical studies prior to ENHANCE have demonstrated that VYTORIN lowered patients' LDL cholesterol more than rosuvastatin, atorvastatin and simvastatin at the doses studied and was able to get more patients to their LDL cholesterol goals (as defined by ATP III). The findings from the Merck/Schering-Plough cholesterol joint venture's ENHANCE clinical trial further confirmed VYTORIN's effectiveness, compared to simvastatin, at lowering LDL cholesterol as well as triglycerides and C-reactive protein (CRP). Specifically, there was a significant difference in LDL cholesterol lowering seen between the treatment groups—58% LDL cholesterol lowering at 24 months on VYTORIN as compared to 41% at 24 months on simvastatin alone. VYTORIN is not indicated for the reduction of CRP.

The ENHANCE surrogate endpoint study was not powered nor designed to assess cardiovascular clinical event outcomes, such as the effectiveness of the drugs at lowering the risk of heart attack and stroke. The Merck/Schering-Plough cholesterol joint venture is currently conducting the IMPROVE-IT trial, a large clinical trial comparing VYTORIN (ezetimibe/simvastatin) and simvastatin in approximately 18,000 patients. The results of the IMPROVE-IT trial will compare the effectiveness of VYTORIN to simvastatin alone in reducing heart attacks and/or strokes.

Schering-Plough's stock price declined significantly in early 2008, from \$26.64 (closing price) on December 31, 2007 to a 2008 low of \$13.86 (closing price) on April 2, 2008 to \$21.08 (closing price) on July 31, 2008, the day before this 10-Q was filed.

*Investigation and Inquiries.* Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its joint venture partner, Merck, have received a number of governmental inquiries and have been the subject of a number of investigations. These include several letters from Congress, including the House Committee on Energy and Commerce, the House Subcommittee on Oversight and Investigations, and the ranking minority member of the Senate Finance Committee, collectively seeking a combination of witness interviews, documents and information on a variety of issues related to the Merck/Schering-Plough cholesterol

joint venture's ENHANCE clinical trial, the companies' sale and promotion of VYTORIN, as well as sales of stock by certain of the companies' corporate officers (including an executive vice president of Schering-Plough) since April 2006. These also include several subpoenas from state officials, including State Attorneys General, and requests for information from U.S. Attorneys seeking similar information and documents.

*Litigation.* In addition, since mid-January 2008, Schering-Plough has become aware of or been served with litigation, including civil class action lawsuits alleging common law and state consumer fraud claims in connection with Schering-Plough's sale and promotion of the Merck/Schering-Plough joint-venture products VYTORIN and ZETIA; several putative shareholder securities class action lawsuits (where several officers are also named defendants) alleging false and misleading statements and omissions by Schering-Plough and its representatives related to the timing of disclosures concerning the ENHANCE results, allegedly in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934; a putative shareholder securities class action lawsuit (where several officers and directors are also named), alleging material misstatements and omissions related to the ENHANCE results in the offering documents in connection with Schering-Plough's 2007 securities offerings, allegedly in violation of the Securities Act of 1933, including Section 11; several putative class action suits alleging that Schering-Plough and certain officers and directors breached their fiduciary duties under ERISA and seeking damages in the amount of losses allegedly suffered by the Plans; a Shareholder Derivative Action alleging that the Board of Directors breached its fiduciary obligations relating to the timing of the release of the ENHANCE results; and a letter on behalf of a single shareholder requesting that the Board of Directors investigate the allegations in the litigation described above and, if warranted, bring any appropriate legal action on behalf of Schering-Plough.

Schering-Plough is cooperating fully with the various investigations and responding to the requests for information, and Schering-Plough intends to vigorously defend the lawsuits that have been filed relating to the ENHANCE study.

#### ***Patent Challenges Under the Hatch-Waxman Act***

Although Schering-Plough does not currently believe any pending Paragraph IV certification proceeding under the Hatch-Waxman Act is material, because there is frequently media and investor interest in such proceedings, Schering-Plough is listing the pending proceedings each quarter. Currently, the following are pending:

in July 2007, Schering-Plough and its licensor, Cancer Research Technologies, Limited, filed a patent infringement action against companies seeking approval of a generic version of certain strengths of TEMODAR capsules;

in March 2007, Schering-Plough and an entity jointly owned with Merck filed a patent infringement action against companies seeking approval of a generic version of ZETIA; and

in September 2006 and dates thereafter, Schering-Plough filed patent infringement actions against companies seeking approval of generic versions of CLARINEX Tablets, CLARINEX Reditabs, CLARINEX D24, and CLARINEX D12.

**Item 1A. Risk Factors**

Schering-Plough's future operating results and cash flows may differ materially from the results described in this 10-Q due to risks and uncertainties related to Schering-Plough's business, including those discussed below. In addition, these factors represent risks and uncertainties that could cause actual results to differ materially from those implied by forward-looking statements contained in this report.

***Key Schering-Plough products generate a significant amount of Schering-Plough's profits and cash flows, and any events that adversely affect the markets for its leading products could have a material and negative impact on results of operations and cash flows.***

Schering-Plough's ability to generate profits and operating cash flow depends largely upon the continued profitability of Schering-Plough's cholesterol franchise, consisting of VYTORIN and ZETIA. In addition, other key products such as REMICADE, NASONEX, TEMODAR, PEGINTRON, CLARINEX, FOLLISTIM, AVELOX, CLARITIN and NUVARING account for a material portion of revenues. As a result of Schering-Plough's dependence on key products, any events that adversely affect the markets for these products could have a significant impact on results of operations. These events include loss of patent protection, increased costs associated with manufacturing, generic or OTC availability of Schering-Plough's product or a competitive product, the discovery of previously unknown side effects, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason.

***There is a high risk that funds invested in research will not generate financial returns because the development of novel drugs requires significant expenditures with a low probability of success.***

There is a high rate of failure inherent in the research to develop new drugs to treat diseases. As a result, there is a high risk that funds invested in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.

***Schering-Plough's success is dependent on the successful development and marketing of new products, which are subject to substantial risks.***

Products that appear promising in development may fail to reach market for numerous reasons, including the following:

findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or pre-clinical testing;

failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications;

lack of economic feasibility due to manufacturing costs or other factors; and

preclusion from commercialization by the proprietary rights of others.

***Intellectual property protection for innovation is an important contributor to Schering-Plough's profitability. Generic forms of Schering-Plough's products may be introduced to the market as a result of the expiration of***

*patents covering Schering-Plough's products, a successful challenge to Schering-Plough's patents, or the at-risk launch of a generic version of a Schering-Plough product, which may have a material and negative effect on results of operations.*

Intellectual property protection is critical to Schering-Plough's ability to successfully commercialize its products. U.S. patents relating to Schering-Plough's significant products are of material importance to Schering-Plough. Upon the expiration or the successful challenge of Schering-Plough's patents covering a product, competitors may introduce lower-priced generic or similar branded versions of that product, which may include Schering-Plough's well-established products.

A generic manufacturer may file an Abbreviated New Drug Application seeking approval after the expiration of the applicable data exclusivity and alleging that one or more of the patents listed in the innovator's New Drug Application are invalid, not infringed or unenforceable. This allegation is commonly known as a Paragraph IV certification. The innovator then has the ability to file suit against the generic manufacturer to enforce its patents. Generic manufacturers have used Paragraph IV certifications extensively to challenge patents on a wide array of innovative pharmaceuticals, and it is anticipated that this trend will continue. In recent years, some generic manufacturers have launched generic versions of products before the ultimate resolution of patent litigation (commonly known as "at-risk" product launches). Generic entry may result in the loss of a significant portion of sales or downward pressures on the prices at which Schering-Plough offers formerly patented products. Please refer to "Legal Proceedings" in Schering-Plough's 2007 10-K/A and subsequent 10-Qs for descriptions of pending intellectual property litigation.

Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies, which could diminish or eliminate sales and profits from those regions and negatively affect Schering-Plough's results of operations. Further, recent court decisions relating to other companies' patents in the U.S., potential U.S. legislation relating to patent reform, as well as regulatory initiatives may result in further erosion of intellectual property protection.

***Patent disputes can be costly to prosecute and defend and adverse judgments could result in damage awards, increased royalties and other similar payments and decreased sales.***

Patent positions can be highly uncertain and patent disputes in the pharmaceutical industry are not unusual. An adverse result in a patent dispute involving Schering-Plough's patents, or the patents of its collaborators, may lead to a determination by a court that the patent is not infringed, invalid, and/or unenforceable. Such an adverse determination could lead to a loss of market exclusivity. An adverse result in a patent dispute involving patents held by a third party may lead to a determination by a court that the patent is infringed, valid, and enforceable. Such an adverse determination may preclude the commercialization of Schering-Plough's products through injunctive relief, and/or may lead to significant financial damages for past and ongoing infringement. Due to the uncertainty surrounding patent litigation, parties may settle patent disputes by obtaining a license under mutually agreeable terms in order to decrease risk of an interruption in manufacturing and/or marketing of its products.

The potential for litigation regarding Schering-Plough's intellectual property rights always exists and may be initiated by third parties attempting to abridge Schering-Plough's rights. Even if Schering-Plough is ultimately successful in a particular dispute, Schering-Plough may incur substantial costs in defending its patents and other intellectual property rights. See "Patent Challenges Under the Hatch-Waxman Act" in Part II, Item 1, "Legal Proceedings" for a list of current Paragraph IV certifications for Schering-Plough products.

***Multi-jurisdictional regulations, including those establishing Schering-Plough's ability to price products, may negatively affect Schering-Plough's sales and profit margins.***

Schering-Plough faces increasing pricing pressure globally from managed care organizations, institutions and government agencies and programs that could negatively affect Schering-Plough's sales and profit margins. For example, in the U.S., the Medicare Prescription Drug Improvement and Modernization Act of 2003 contains a prescription drug benefit for individuals who are eligible for Medicare. The prescription drug benefit became effective on January 1, 2006 and has resulted in increased use of generics and increased purchasing power of those negotiating on behalf of Medicare recipients.

In addition to legislation concerning price controls, other trends could adversely affect Schering-Plough's sales and profit margins. These trends include legislative or regulatory action relating to pharmaceutical pricing and reimbursement, health care reform initiatives and drug importation legislation and involuntary approval of medicines



for OTC use. These trends also include non-governmental initiatives and practices such as consolidation among customers, managed care practices and health care costs containment. Increasingly, market approval, reimbursement of products, prescribers practices and policies of third-party payors may be

influenced by health technology assessments by the National Institute for Health and Clinical Excellence in the UK and other such organizations.

In the U.S., as a result of the government's efforts to reduce health care expenditures and other payors' efforts to reduce health care costs, Schering-Plough faces increased pricing pressure as payors continue to seek price discounts with respect to Schering-Plough's products.

In other countries, many governmental agencies strictly control, directly or indirectly, the prices at which pharmaceutical products are sold. In these markets, cost control methods including restrictions on physician prescription levels and patient reimbursements; emphasis on greater use of generic drugs; and across-the-board price cuts may decrease revenues internationally.

***Through the acquisition of OBS, Schering-Plough acquired marketed products and pipeline projects in new therapeutic areas, including women's health and fertility, anesthesia, and neuroscience, each of which carry unique risks and uncertainties which could have a negative impact on future results of operations.***

With its acquisition of OBS, Schering-Plough acquired products in additional therapeutic areas. Each therapeutic area presents a different risk profile, including different benefits and safety issues that must be balanced by Schering-Plough and the regulators as various research and development and marketing decisions are made; unique product liability risks; different patient and prescriber priorities; and different societal pressures. While adding new therapeutic areas may strengthen the business by increasing sales and profits; making the combined company more relevant to patients and prescribers; and diversifying enterprise risk across more areas, such positives may not outweigh the additional risk in a particular therapeutic area or could result in unanticipated costs that could be material.

***Market forces continue to evolve and can impact Schering-Plough's ability to sell products or the price Schering-Plough can charge for products.***

A number of intermediaries are involved between drug manufacturers, such as Schering-Plough, and patients who use the drugs. These intermediaries impact the patient's ability, and their prescribers' ability, to choose and pay for a particular drug, which may adversely affect sales of a particular Schering-Plough drug. These intermediaries include health care providers, such as hospitals and clinics; payors and their representatives, such as employers, insurers, managed care organizations and governments; and others in the supply chain, such as pharmacists and wholesalers. Examples include: payors that require a patient to first fail on one or more generic, or less expensive branded drugs, before reimbursing for a more effective, branded product that is more expensive; hospitals that stock and administer only a generic product to in-patients; managed care organizations that may penalize doctors who prescribe outside approved formularies which may not include branded products when a generic is available; and pharmacists who receive larger revenues when they dispense a generic drug over a branded drug. Further, the intermediaries are not required to routinely provide transparent data to patients comparing the effectiveness of generic and branded products or to disclose their own economic benefits that are tied to steering patients toward, or requiring patients to use, generic products rather than branded products.

***Government investigations involving Schering-Plough could lead to the commencement of civil and/or criminal proceedings involving the imposition of substantial fines, penalties and injunctive or administrative remedies, including exclusion from government reimbursement programs, which could give rise to other investigations or litigation by government entities or private parties.***

Schering-Plough cannot predict whether future or pending investigations to which it may become subject would lead to a judgment or settlement involving a significant monetary award or restrictions on its operations.

The pricing, sales and marketing programs and arrangements and related business practices of Schering-Plough and other participants in the health care industry are under increasing scrutiny from federal and state regulatory, investigative, prosecutorial and administrative entities. These entities include the Department of

Justice and its U.S. Attorney's Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. Many of the health care laws under which certain of these governmental entities operate, including the federal and state anti-kickback statutes and statutory and common law false claims laws, have been construed broadly by the courts and permit the government entities to exercise significant discretion. In the event that any of those governmental entities believes that wrongdoing has occurred, one or more of them could institute civil or criminal proceedings which, if resolved unfavorably, could subject Schering-Plough to substantial fines, penalties and injunctive or administrative remedies, including exclusion from government reimbursement programs. In addition, an adverse outcome to a government investigation could prompt other government entities to commence investigations of Schering-Plough or cause those entities or private parties to bring civil claims against it. Schering-Plough also cannot predict whether any investigations will affect its marketing practices or sales. Any such result could have a material adverse impact on Schering-Plough's results of operations, cash flows, financial condition, or its business.

A number of governmental entities in the U.S. have made inquiries or initiated investigations into the timing and disclosures relating to the ENHANCE clinical trial, as well as the timing of certain stock sales by an executive vice president. These include several letters from Congress, investigations by state Attorneys General offices, and requests for information from U.S. Attorney's Offices.

Regardless of the merits or outcomes of any investigation, government investigations are costly, divert management's attention from Schering-Plough's business and may result in substantial damage to Schering-Plough's reputation.

***There are other legal matters in which adverse outcomes could negatively affect Schering-Plough's business.***

Unfavorable outcomes in other pending litigation matters, or in future litigation, including litigation concerning product pricing, securities law violations, product liability claims, ERISA matters, patent and intellectual property disputes, and antitrust matters could preclude the commercialization of products, negatively affect the profitability of existing products and could subject Schering-Plough to substantial fines, penalties and injunctive or administrative remedies, including exclusion from government reimbursement programs. Any such result could materially and adversely affect Schering-Plough's results of operations, cash flows, financial condition, or its business.

Further, aggressive plaintiffs counsel often file litigation on a wide variety of allegations whenever there is media attention or negative discussion about the efficacy or safety of a product and whenever the stock price is volatile; even when the allegations are groundless considerable resources are needed to respond to such litigation.

Please refer to Legal Proceedings in Item 3 in Schering-Plough's 2007 10-K/A and Part II, Item 1, Legal Proceedings, in this 10-Q for descriptions of significant pending litigation.

***Issues concerning the Merck/Schering-Plough Cholesterol Joint Venture's clinical trials could have a material adverse effect on the joint venture's sales of VYTORIN and ZETIA, which in turn could have a material adverse impact on Schering-Plough's financial condition.***

See Recent Cholesterol Clinical Trials, in part II of this 10-Q and ENHANCE Matter in Part II, Item 1, Legal Proceedings of this 10-Q for background information about the Merck/Schering-Plough cholesterol joint venture's clinical trials and related matters.

There was significant negative media surrounding the release of the ENHANCE results. As the Merck/Schering-Plough cholesterol joint venture's ENHANCE and SEAS clinical trial results are further reviewed, VYTORIN and ZETIA may receive additional media attention, which could lead to reduced sales, or affect enrollment in clinical trials. In the first half of 2008, sales of VYTORIN and ZETIA in the U.S. decreased by 16 percent

compared to the first half of 2007. If sales of these products continue to trend down further in the U.S., Schering-Plough's results of operations, cash flow, financial position, business and

prospects could also be materially adversely affected. In addition, current or future investigations, analysis of the ENHANCE data by various agencies, litigation concerning the sale and promotion of these products, or the securities and other class action litigation relating to such matters could, if resolved unfavorably to Schering-Plough or the joint venture, have a material adverse effect on Schering-Plough's results of operations, cash flow and financial position.

***Schering-Plough and third parties acting on its behalf are subject to governmental regulations, and the failure to comply with, as well as the costs of compliance with, these regulations may adversely affect Schering-Plough's results of operations, cash flow and financial position.***

Manufacturing and research practices of Schering-Plough and third parties acting on its behalf must meet stringent regulatory standards and are subject to regular inspections. The cost of regulatory compliance, including that associated with compliance failures, can materially affect Schering-Plough's results of operations, cash flow and financial position. Failure to comply with regulations, which include pharmacovigilance reporting requirements and standards relating to clinical, laboratory and manufacturing practices, can result in suspension or termination of clinical studies, delays or failure in obtaining the approval of drugs, seizure or recalls of drugs, suspension or revocation of the authority necessary for the production and sale of drugs, withdrawal of approval, fines and other civil or criminal sanctions.

Schering-Plough also is subject to other regulations, including environmental, health and safety, and labor regulations.

***Developments following regulatory approval may adversely affect sales of Schering-Plough's products.***

Even after a product reaches market, certain developments following regulatory approval, including results in post-marketing Phase IV trials, may decrease demand for Schering-Plough's products, including the following:

- the re-review of products that are already marketed;
- new scientific information and evolution of scientific theories;
- the recall or loss of marketing approval of products that are already marketed;
- changing government standards or public expectations regarding safety, efficacy or labeling changes; and
- greater scrutiny in advertising and promotion.

In the past several years, clinical trials and post-marketing surveillance of certain marketed drugs of competitors within the industry have raised safety concerns that have led to recalls, withdrawals or adverse labeling of marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials have led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.

In addition, following the wake of product withdrawals of other companies and other significant safety issues, health authorities such as the FDA, the European Medicines Agency and the Pharmaceuticals and Medicines Device Agency have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications and are re-reviewing select products that are already marketed, adding further to the uncertainties in the regulatory processes. There is also greater regulatory scrutiny, especially in the U.S., on advertising and promotion and in particular,

direct-to-consumer advertising.

If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of Schering-Plough's products, it could significantly reduce demand for the product

or may require Schering-Plough to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the current environment in which all pharmaceutical companies operate, Schering-Plough is at risk for product liability claims for its products.

***New products and technological advances developed by Schering-Plough's competitors may negatively affect sales.***

Schering-Plough operates in a highly competitive industry. Schering-Plough competes with a large number of multinational pharmaceutical companies, biotechnology companies and generic pharmaceutical companies. Many of Schering-Plough's competitors have been conducting research and development in areas served both by Schering-Plough's current products and by those products Schering-Plough is in the process of developing. Competitive developments that may impact Schering-Plough include technological advances by, patents granted to, and new products developed by competitors or new and existing generic, prescription and/or OTC products that compete with products of Schering-Plough or the Merck/Schering-Plough cholesterol joint venture. In addition, it is possible that doctors, patients and providers may favor those products offered by competitors due to safety, efficacy, pricing or reimbursement characteristics, and as a result Schering-Plough will be unable to maintain its sales for such products.

***Competition from third parties may make it difficult for Schering-Plough to acquire or license new products or product candidates (regardless of stage of development) or to enter into such transactions on terms that permit Schering-Plough to generate a positive financial impact.***

Schering-Plough depends on acquisition and in-licensing arrangements as a source for new products. Opportunities for obtaining or licensing new products are limited, however, and securing rights to them typically requires substantial amounts of funding or substantial resource commitments. Schering-Plough competes for these opportunities against many other companies and third parties that have greater financial resources and greater ability to make other resource commitments. Schering-Plough may not be able to acquire or license new products, which could adversely impact Schering-Plough and its prospects. Schering-Plough may also have difficulty acquiring or licensing new products on acceptable terms. To secure rights to new products, Schering-Plough may have to make substantial financial or other resource commitments that could limit its ability to produce a positive financial impact from such transactions.

***Schering-Plough relies on third-party relationships for its key products, and the conduct and changing circumstances of such third parties may adversely impact the business.***

Schering-Plough has several relationships with third parties on which Schering-Plough depends for many of its key products. Very often these third parties compete with Schering-Plough or have interests that are not aligned with the interests of Schering-Plough. Notwithstanding any contracts Schering-Plough has with these third parties, Schering-Plough may not be able to control or influence the conduct of these parties, or the circumstances that affect them, either of which could adversely impact Schering-Plough.

The relationships are long-standing and, as the third party's work and Schering-Plough's work evolves, priorities and alignments also change. At times new issues develop that were not anticipated at the time contracts were negotiated. These new issues, and related uncertainties in the contracts, also can adversely impact Schering-Plough.

***Schering-Plough's global operations expose Schering-Plough to additional risks, and any adverse event could have a material negative impact on results of operations.***

A majority of Schering-Plough's operations are outside the U.S. With the acquisition of OBS in late 2007, Schering-Plough's global operations in Human Prescription Pharmaceuticals and Animal Health increased.



Acquisitions, such as the recently completed purchase of OBS, further expanded the size, scale and scope of its global operations. Risks inherent in conducting a global business include:

changes in medical reimbursement policies and programs and pricing restrictions in key markets;

multiple regulatory requirements that could restrict Schering-Plough's ability to manufacture and sell its products in key markets;

trade protection measures and import or export licensing requirements;

diminished protection of intellectual property in some countries; and

possible nationalization and expropriation.

In addition, there may be changes to Schering-Plough's business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease.

***The integration of the businesses of Schering-Plough and OBS to create a combined company is a complex process and may be subject to unforeseen developments, which could have an adverse impact on the results of future operations.***

As the two companies are combined, the workforces of Schering-Plough and OBS will continue to face uncertainties until the completion of the integration phase. Cultural integration particularly in trans-Atlantic transactions are complex and can take several years. Although substantial efforts are being made to complete the integration phase as quickly as possible, it is difficult to predict how long the integration phase will last.

The workforces of both companies are learning to use new processes as work is integrated and streamlined. Further, for those employees of the new combined company who have not in the past worked for a U.S.-based global company, the applicable regulatory requirements are different in a number of respects. While substantial efforts are being made to facilitate smooth execution of integration including thorough training and transparent and motivational employee communications there may be an increased risk of slower execution of various work processes, repeated execution to achieve quality standards and reputational harm in the event of a compliance failure with new and complex regulatory requirements, even if such a failure were inadvertent. Any such events could have an adverse impact on the results of future operations.

***The acquisition of OBS expanded Schering-Plough's animal health business worldwide, which increases the risk that negative events in the animal health industry could have a negative impact on future results of operations.***

Through the acquisition of OBS' animal health businesses, Schering-Plough's global animal health business is now a more significant business segment. The combined company's future sales of key animal health products could be adversely impacted by a number of risk factors including certain that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as Bovine Spongiform Encephalopathy ( BSE ) or mad cow disease, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely impact Schering-Plough's results of operations. Also, the outbreak of any highly contagious diseases near Schering-Plough's main production sites could require Schering-Plough to immediately halt production of vaccines at such sites or force Schering-Plough to incur substantial expenses in procuring raw materials or vaccines elsewhere. Other risks specific to animal health include epidemics and pandemics, government procurement and pricing practices, weather and global agribusiness economic events. As the animal health segment of Schering-Plough's business becomes more significant, the impact of any such events on future results of operations would also become more significant.



***The acquisition of OBS increased Schering-Plough's biologics human and animal health product offerings, including animal health vaccines. Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.***

The successful development, testing, manufacturing and commercialization of biologics, particularly human and animal health vaccines, is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics, including:

There may be limited access to and supply of normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions such as the U.S. and European states within the EU, could result in restricted access to, or transport or use of, such materials. If Schering-Plough loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, Schering-Plough may not be able to conduct research activities as planned and may incur additional development costs.

The development, manufacturing and marketing of biologics are subject to regulation by the FDA, the European Medicines Agency and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the U.S., a Biologics License Application, including both preclinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates and FDA approval for the release of each manufactured lot.

Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, Schering-Plough may be required to provide pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes.

Biologics are frequently costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.

The use of biologically derived ingredients can lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. Any of these events could result in substantial costs.

There currently is no process in the U.S. for the submission or approval of generic biologics based upon abbreviated data packages or a showing of sameness to another approved biologic, but there is public dialogue at the FDA and in Congress regarding the scientific and statutory basis upon which such products, known as biosimilars or follow-on biologics, could be approved and marketed in the U.S. Schering-Plough cannot be certain when Congress will create a statutory pathway for the approval of biosimilars, and Schering-Plough cannot predict what impact, if any, the approval of biosimilars would have on the sales of Schering-Plough products in the U.S. In Europe, however, the EMEA has issued guidelines for approving biological products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of Schering-Plough's products were approved in Europe, it could have a negative effect on sales of the product.

***Schering-Plough is exposed to market risk from fluctuations in currency exchange rates and interest rates.***

Schering-Plough operates in multiple jurisdictions and, as such, virtually all sales are denominated in currencies of the local jurisdiction. Additionally, Schering-Plough has entered and will enter into acquisition, licensing, borrowings or other financial transactions that may give rise to currency and interest rate exposure.

Since Schering-Plough cannot, with certainty, foresee and mitigate against such adverse fluctuations, fluctuations in currency exchange rates and interest rates could negatively affect Schering-Plough's results of operations and/or cash flows.

In order to mitigate against the adverse impact of these market fluctuations, Schering-Plough will from time to time enter into hedging agreements. While hedging agreements, such as currency options and interest rate swaps, limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks are costly and not always successful.

***Insurance coverage for product liability may be limited, cost prohibitive or unavailable.***

Schering-Plough maintains insurance coverage with such deductibles and self-insurance to reflect market conditions (including cost and availability) existing at the time it is written, and the relationship of insurance coverage to self-insurance varies accordingly. For certain products, third-party insurance is increasingly cost prohibitive, available on more limited terms than past coverage, or unavailable.

***Schering-Plough is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations.***

Schering-Plough is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining Schering-Plough's tax liabilities, and Schering-Plough's tax returns are periodically examined by various tax authorities. Schering-Plough believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued.

In addition, Schering-Plough may be impacted by changes in tax laws including tax rate changes, changes to the laws related to the remittance of foreign earnings, new tax laws and revised tax law interpretations in domestic and foreign jurisdictions.

## **Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

This table provides information with respect to purchases by Schering-Plough of its common shares during the second quarter of 2008.

<b>Period</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</b>
April 1, 2008 through April 30, 2008	1,835,732(1)	\$ 18.57	N/A	N/A

Edgar Filing: SCHERING PLOUGH CORP - Form 10-Q

May 1, 2008 through May 31, 2008	19,458(1)	\$	19.03	N/A	N/A
June 1, 2008 through June 30, 2008	8,164(1)	\$	19.35	N/A	N/A
<b>Total April 1, 2008 through June 30, 2008</b>	1,863,354(1)	\$	18.58	N/A	N/A

(1) All of the shares included in the table above were repurchased pursuant to Schering-Plough's stock incentive program and represent shares delivered to Schering-Plough by option holders for payment of the exercise price and tax withholding obligations in connection with stock options and stock awards.

**Item 4. Submission of Matters to a Vote of Security Holders**

The annual meeting of shareholders was held on May 16, 2008 and shareholders voted on the following matters with the results indicated:

(1) Election of Directors: Thirteen nominees for director were elected for a one-year term by a vote of shares as follows: Hans W. Becherer received 1,364,103,512 votes for his election (93.93% of shares voted) and 88,086,331 votes were withheld (6.07% of shares voted); Thomas J. Colligan received 1,428,056,720 votes for his election (98.34% of shares voted) and 24,133,123 votes were withheld (1.66% of shares voted); Fred Hassan received 1,417,219,453 votes for his election (97.59% of shares voted) and 34,970,390 votes were withheld (2.41% of shares voted); C. Robert Kidder received 1,383,794,883 votes for his election (95.29% of shares voted) and 68,394,960 votes were withheld (4.71% of shares voted); Eugene R. McGrath received 1,427,807,651 votes for his election (98.32% of shares voted) and 24,382,192 votes were withheld (1.68% of shares voted); Carl E. Mundy received 1,414,557,102 votes for his election (97.41% of shares voted) and 37,632,741 votes were withheld (2.59% of shares voted); Antonio M. Perez received 1,425,862,182 votes for his election (98.19% of shares voted) and 26,327,661 votes were withheld (1.81% of shares voted); Patricia F. Russo received 1,370,950,772 votes for her election (94.41% of shares voted) and 81,239,071 votes were withheld (5.59% of shares voted); Jack L. Stahl received 1,384,355,679 votes for his election (95.33% of shares voted) and 67,834,164 votes were withheld (4.67% of shares voted); Craig B. Thompson received 1,423,691,268 votes for his election (98.04% of shares voted) and 28,498,575 votes were withheld (1.96% of shares voted); Kathryn C. Turner received 1,422,409,024 votes for her election (97.95% of shares voted) and 29,780,819 votes were withheld (2.05% of shares voted); Robert F.W. van Oordt received 1,414,558,551 votes for his election (97.41% of shares voted) and 37,631,292 votes were withheld (2.59% of shares voted); and Arthur F. Weinbach received 1,383,877,789 votes for his election (95.30% of shares voted) and 68,312,054 votes were withheld (4.70% of shares voted).

(2) Ratification of Auditors: The designation by the Audit Committee of Deloitte & Touche LLP to audit the books and accounts of the Company for the year ending December 31, 2008 was ratified with a vote of 1,423,195,783 shares for, 15,215,321 shares against and 13,777,739 abstentions.

**Item 6. Exhibits**

<b>Exhibit Number</b>	<b>Description</b>	<b>Location</b>
12	Computation of Ratio of Earnings to Fixed Charges	Attached
15	Awareness letter	Attached
31.1	Sarbanes-Oxley Act of 2002, Section 302 Certification for Chairman of the Board and Chief Executive Officer.	Attached
31.2	Sarbanes-Oxley Act of 2002, Section 302 Certification for Executive Vice President and Chief Financial Officer.	Attached
32.1	Sarbanes-Oxley Act of 2002, Section 906 Certification for Chairman of the Board and Chief Executive Officer.	Attached
32.2		Attached



Sarbanes-Oxley Act of 2002, Section 906  
Certification for Executive Vice President and  
Chief Financial Officer.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SCHERING-PLOUGH CORPORATION  
(Registrant)

By */s/ Steven H. Koehler*  
Steven H. Koehler  
Vice President and Controller  
(Duly Authorized Officer  
and Chief Accounting Officer)

Date: July 31, 2008